Introduction {#s1}
============

Immune responses require precise, dynamic gene regulation that must activate rapidly as threats rise and resolve efficiently as they clear. Post-transcriptional control of mRNA abundance and expression by RNA binding proteins (RBPs) is a key layer of this response that can enact rapid, signal-responsive changes ([@bib23]; [@bib17]), but knowledge of specific functional roles for dedicated RBPs remains limited.

AU-rich elements (AREs) in mRNA 3'-untranslated regions (3'-UTR) facilitate post-transcriptional control of many immune functions, including cytokine expression, signal transduction, and immediate-early transcriptional response ([@bib10]; [@bib45]; [@bib8]). Many RBPs bind AREs, with diverse ensuing effects on RNA turnover, translation, and localization ([@bib46]; [@bib52]; [@bib56]). The Zinc finger binding protein 36 (ZFP36) family of proteins are prototypical ARE-binding factors with distinctive, activation-dependent expression in hematopoietic cell lineages ([@bib39]; [@bib9]). The family includes three somatic paralogs: ZFP36 (a.k.a Tristetraprolin, TTP), ZFP36L1 (a.k.a. butyrate responsive factor 1, BRF1), and ZFP36L2 (a.k.a BRF2) with highly homologous CCCH zinc-finger RNA binding domains ([@bib3]).

In many contexts, the archetypal paralog ZFP36 de-stabilizes target mRNAs by binding 3'-UTR AREs and recruiting deadenylation and degradation factors ([@bib5]; [@bib30]). More recently, evidence has begun to emerge for roles in translation ([@bib48]; [@bib52]) but in vivo function and context have not been established. While many aspects remain unsettled, ZFP36 is clearly critical for immune function, as its loss causes a systemic inflammatory disease in mice ([@bib49]). A key feature of this syndrome is aberrant stabilization and over-expression of *Tnf *in myeloid cells, particularly macrophages ([@bib9]), where UV cross-linking and immunoprecipitation (CLIP) analyses have further supported direct regulation ([@bib51]; [@bib43]). However, this role does not fully account for ZFP36 function in vivo, as underscored by reports that myeloid-specific deletions of *Zfp36* do not recapitulate spontaneous autoimmunity ([@bib38]; [@bib24]).

Increasing evidence points to important functions for ZFP36 proteins in adaptive immunity. Dual ablation of paralogs *Zfp36l1* and *Zfp36l2* in T cells arrests thymopoeisis at the double-negative stage, and causes lethal lymphoma linked to *Notch1* dysregulation ([@bib20]). This role in restraining aberrant proliferation was later extended to B-cell development and lymphoma ([@bib16]; [@bib41]), but the severe phenotype precluded analysis of ZFP36 family function in mature T cells. Consistent with such a function, in vitro studies suggest ZPF36 regulates the expression of T cell-derived cytokines, including IL-2, IFN-γ, and IL-17, that mediate lymphocyte homeostasis, microbial response, and inflammation ([@bib28]; [@bib35]; [@bib34]). The landscape of ZFP36 targets beyond these limited cases in T cells is unknown, but will be the key to understanding its emerging roles in inflammation, autoimmunity, and malignant cell growth ([@bib36]).

To determine ZFP36 functions in T cells, we employed high-throughput sequencing of UV-cross-linking and immunoprecipitation (HITS-CLIP) to generate a definitive set of ZFP36 RNA targets. HITS-CLIP utilizes in vivo UV-cross-linking to induce covalent bonds between RBPs and target RNAs, allowing stringent immunopurification and thus rigorous identification of direct binding events ([@bib29]; [@bib53]). These new ZFP36 RNA binding maps pointed to roles in regulating T-cell activation kinetics and proliferation, a function confirmed in extensive functional assays, and in vivo studies demonstrating a critical role in anti-viral immunity. Our results illuminate novel functions for ZFP36 in adaptive immunity, laying groundwork for understanding and modulating its activity in disease.

Results {#s2}
=======

ZFP36 dynamics during T-cell activation {#s2-1}
---------------------------------------

ZFP36 expression is induced upon T-cell activation ([@bib39]). We examined its precise kinetics following activation of primary mouse CD4 +T cells by Western analysis with custom ZFP36 antisera generated against a C-terminal peptide of mouse ZFP36. Protein levels peaked \~4 hr post-activation and tapered gradually through 72 hr, and were re-induced by re-stimulation 3 days post-activation ([Figure 1A](#fig1){ref-type="fig"}). ZFP36 expression depended on both TCR stimulation, provided by anti-CD3, and co-stimulation, provided by co-cultured dendritic cells (DCs) ([Figure 1B](#fig1){ref-type="fig"}). A similar pattern of transient ZFP36 induction occurred in activated CD8 +T cells ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}).

![HITS-CLIP as a transcriptome-wide screen for ZFP36 function in T cells.\
(**A**) Immunoblots with pan-ZFP36 antisera after activation of naïve CD4 +T cells in DC co-cultures, and with re-stimulation at day 3. Antibody and MW markers are shown on the left. NS\* indicates a non-specific band. (**B**) Immunoblotting with pan-ZFP36 antisera 4 hr after activation of naïve CD4 +T cells, testing dependence on TCR stimulation (α-CD3), and co-stimulation (DCs or α-CD28). (**C**) ZFP36 HITS-CLIP design. (**D**) Representative autoradiogram of ZFP36 CLIP from activated CD4 +T cells using pan-ZFP36 antisera, with pre-immune and no-UV controls. Signal in *Zfp36* KO cells is due to capture of ZFP36L1 RNP complexes. (**E**) The most enriched binding motifs and (**F**) annotation of binding sites from WT and *Zfp36* KO cells. (**G**) Overlap of binding sites in WT and *Zfp36* KO cells, stratified by peak height (PH). CLIP data are compilation of 4 experiments, with 3--5 total biological replicates were condition. (**H**) RNAseq in WT and *Zfp36* KO CD4 +T cells activated under Th1 conditions for 4 hr. Log2-transformed fold-changes (KO/WT) are plotted as a cumulative distribution function (CDF), for mRNAs with 3'UTR, CDS, or no significant ZFP36 HITS-CLIP sites. Numbers of mRNAs in each category (**n**) and p-values from two-tailed Kolmogorov-Smirnov (KS) tests are shown. RNAseq data is a compilation of 2 experiments, with 3--4 biological replicates per condition.](elife-33057-fig1){#fig1}

Western blot analysis showed multiple bands at \~40--50 kD, indicating several isoforms. Notably, isoforms running above the predicted molecular weight (MW) of ZFP36 (36 kD) pre-dominated early after activation, and are consistent with previously reported hyperphosphorylation ([@bib38]). In addition, partial conservation of the immunizing peptide in ZFP36L1 and ZFP36L2 raised the possibility of paralog cross-reactivity. Western analyses with recombinant constructs confirmed ZFP36, ZFP36L1, and ZFP36L2 are readily detected with our custom antisera (henceforth, pan anti-ZFP36; [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Commercial paralog-specific antibodies were identified, and Western analysis showed that both ZFP36 and ZFP36L1 were induced by T-cell activation ([Figure 1---figure supplement 1B--C](#fig1s1){ref-type="fig"}). ZFP36L2, expected to run at \~62 kD, was not detected under any conditions examined. Analysis of *Zfp36* KO T cell lysates with pan ZFP36 antisera showed \~50% reduced signal compared to WT. We conclude that the residual signal is likely due to persistent expression of ZFP36L1, which is highly homologous and of similar size to ZFP36. Collectively, these results demonstrate activation-dependent expression of ZFP36 and ZFP36L1 in T cells, and suggest activated *Zfp36* KO T cells have partial loss (\~50%) of pan ZFP36 expression ([Figure 1---figure supplement 1D](#fig1s1){ref-type="fig"}).

The characterization of *Zfp36* as an immediate early response gene in various cell types established transcription as a mechanism of its activation-induced expression ([@bib25]). Interestingly, *Zfp36* (RPKM = 22.5) and *Zfp36l1* (RPKM = 8.2) mRNAs are robustly present in RNAseq data from naïve CD4 +T cells, despite an absence of detectable protein by western blotting. ZFP36L2 was not detected in any conditions examined, but its mRNA was also detected in naïve cells (RPKM = 30.2). These observations indicate that post-transcriptional mechanisms regulate expression of ZFP36 paralogs in T cells.

Transcriptome-wide identification of ZFP36 target RNAs in CD4 +T cells {#s2-2}
----------------------------------------------------------------------

The striking pattern of ZFP36/L1 expression in T cells led us to develop ZFP36 HITS-CLIP as a screen for its biological function ([Figure 1C--F](#fig1){ref-type="fig"}; [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Notably, ZFP36/L1 RNPs isolated by CLIP from activated CD4 +T cells sera exhibited high molecular weight (MW) complexes resistant to detergent, heat, and RNAse, consistent with a pattern previously observed in ZFP36 CLIP in macrophages ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}; \[[@bib43]\]). This RNP signal pattern was dependent on UV irradiation, and was observed with two different anti-pan-ZFP36 but neither pre-immune sera.

Given prior evidence that ZFP36 regulates T-helper type-1 (Th1) cytokines (e.g. TNF-α and IFN-γ), we next generated a comprehensive map of ZFP36/L1 binding sites by HITS-CLIP using anti-pan-ZFP36 in WT CD4 +T cells, activated for 4 hr under Th1-polarizing conditions ([@bib35]; [@bib9]). 5132 robust binding sites were defined, requiring a peak height (PH) \>5, and support from at least 3 (of five total) biological replicates and two different pan-ZFP36 antisera ([Supplementary file 1A](#supp1){ref-type="supplementary-material"}; \[[@bib44]; [@bib32]\]). Consistent with identification of bonafide ZFP36/L1 binding events, HITS-CLIP recovered the known AU-rich ZFP36 consensus motif at high significance, along with reported binding sites in *Tnf*, *Ifng* and other targets ([Figure 1E](#fig1){ref-type="fig"}; [Supplementary file 1A](#supp1){ref-type="supplementary-material"}; \[[@bib4]\]). Globally, ZFP36/L1 sites confirmed a preponderance of 3'-UTR binding (\>75%), and showed substantial binding in coding sequence (CDS;\~6.5%) and introns (5.4%) ([Figure 1F](#fig1){ref-type="fig"}). Separate analysis of low and high MW RNP complexes showed similar transcript localization and motif enrichment, all consistent with ZFP36 binding ([Figure 1---figure supplement 2B](#fig1s2){ref-type="fig"}). This analysis indicates the presence of large, stable ZFP36 complexes in vivo, consistent with stable multimers ([@bib6]; [@bib7]). Subsequently, CLIP reads from different MW regions were pooled to maximize dataset depth.

To examine possible paralog specificity, we also mapped ZFP36L1 sites by HITS-CLIP in *Zfp36* KO CD4+T cells under identical conditions. As in western analysis ([Figure 1---figure supplement 1C--D](#fig1s1){ref-type="fig"}), *Zfp36* KO samples showed reduced but significant CLIP signal compared to WT ([Figure 1D](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2A](#fig1s2){ref-type="fig"}), representing ZFP36L1-RNA complexes. Sites in WT and *Zfp36* KO cells showed very similar enriched motifs and transcript localizations, indicating that ZFP36 and ZFP36L1 have similar binding profiles in vivo ([Figure 1E--F](#fig1){ref-type="fig"}, [Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}, [Supplementary file 1B](#supp1){ref-type="supplementary-material"}). Majorities of robust sites (53%) and target mRNAs (66%) identified in WT cells were found independently in *Zfp36* KO cells, and site overlap was far greater (\>90%) for peaks of increasing magnitude ([Figure 1G](#fig1){ref-type="fig"}). A subset of potential ZFP36L1-specific sites was identified only in *Zfp36* KO cells (n = 675; [Supplementary file 1C](#supp1){ref-type="supplementary-material"}), although these showed similar features to ZFP36 sites overall ([Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}; third panel). Thus, these analyses do not exclude paralog specificity at some sites, but indicate broadly overlapping in vivo RNA binding for ZFP36 and ZFP36L1 reflecting their high homology.

Secondary enriched motifs revealed additional properties of ZFP36/L1 target sites. The second top motif resembled the known recognition sequence for polyadenylation factor CFI(m)25 ([@bib54]). Accordingly, ZFP36 binding in 3'UTRs was most concentrated in the vicinity of expected polyA sites,\~50 nucleotides before transcript ends ([Figure 1---figure supplement 2D](#fig1s2){ref-type="fig"}). Analysis of CDS-specific binding revealed the AU-rich ZFP36 motif, along with strong enrichment of the 5' splice site (5'-ss) consensus ([Figure 1---figure supplement 2E](#fig1s2){ref-type="fig"}). Cross-link-induced truncations (CITS) clarified that CDS peaks are centered within coding exons, but supporting CLIP reads often spanned the exon-intron boundary. Thus, at least a subset of CDS binding by ZFP36 occurs prior to pre-mRNA splicing in the nucleus.

ZFP36 represses target mRNA abundance and translation during T-cell activation {#s2-3}
------------------------------------------------------------------------------

We next employed RNA profiling strategies to determine the functional effects of ZFP36/L1 binding. RNAseq analysis in WT and *Zfp36* KO CD4 +T cells activated under conditions identical to our HITS-CLIP analyses uncovered two main effects. First, a small number of mRNAs that were silent in WT cells, including numerous immunoglobulin loci, were detected at low to moderate levels in KO cells ([Figure 1---figure supplement 3A](#fig1s3){ref-type="fig"}). These mRNAs lacked evidence of ZFP36/L1 binding, both in HITS-CLIP data and direct motifs searches, suggesting they are not direct targets. Given established chromatin regulation of many of these loci (i.e. Ig genes) and the on-off nature of the changes, dysregulated transcriptional silencing is a potential explanation, but is likely to be a secondary effect of ZFP36 loss of function. The second main effect emerged from a global analysis, which showed ZFP36 binding in 3'UTR (p=4.44×10^−16^; Kolmogorov-Smirnoff \[KS\]) and CDS (p=5.33×10^−11^) correlated to subtle but highly significant shifts toward greater mRNA abundance in *Zfp36* KO cells, relative to mRNAs with no binding sites ([Figure 1H](#fig1){ref-type="fig"}). This correlation was not observed for mRNAs with binding exclusively in introns, and we did not find evidence in these data that ZFP36/L1 binding correlated with altered usage of proximal splice or polyA sites (not shown). The same pattern was also observed when considering a more stringently defined of sites set overlapping statistically robust CITS ([Figure 1---figure supplement 3B](#fig1s3){ref-type="fig"}).

The overall trend in transcriptome profiling is consistent with evidence that ZFP36 represses RNA abundance ([@bib30]). However, stratification of sites by the magnitude of ZFP36 CLIP binding allowed resolution of potentially complex effects. For 3'UTR binding, ZFP36 targets overall showed a significant shift in abundance, but mRNAs containing the top 20% most robust sites (ranked by peak height \[PH\], see Materials and methods) showed no significant effect. Thus, a higher degree of binding correlated with less effect on RNA abundance in the absence of ZFP36 ([Figure 1---figure supplement 3C](#fig1s3){ref-type="fig"}). This trend was not observed for CDS sites, where the top 20% showed a similar shift to sites overall ([Figure 1---figure supplement 3D](#fig1s3){ref-type="fig"}). Thus, our analyses show a trend of negative regulation of RNA abundance in this context, but with blunted effects for highly robust binding sites in 3'UTR (see Discussion).

We next examined in more detail the effects of ZFP36 regulation for HITS-CLIP targets with highly robust 3'UTR binding in T cells. Activation marker CD69, apoptosis regulator BCL2, and effector cytokines TNF and IFNG showed significantly increased protein levels in *Zfp36* KO versus WT T cells 4 hr after activation ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Of these, only *Bcl2* showed increased mRNA abundance. *Tnf, Ifng*, and *Cd69* were all among the top 20% of targets as defined by CLIP binding magnitude (PH), thus supporting the trend in our global analyses that some highly robust binding targets show little regulation at the level of mRNA abundance in this context. The effects on protein level in the absence of changes in mRNA abundance suggested regulation of translation. We tested this principle by constructing GFP fluorescent reporters with an intact 3'UTRs (WT-UTR), or variants with the CLIP-defined ZFP36 binding site deleted (Δ-UTR; [Figure 2B](#fig2){ref-type="fig"}), for *Cd69, Tnf, and Ifng*. In 293 cells, ZFP36 strongly repressed protein expression for all three WT-UTR reporters, while showing weaker (*Tnf* and *Ifng*) or no (*Cd69)* repression of mRNA levels. Of note, the Δ-UTR constructs showed increased protein levels both in the presence and absence of ZFP36. This indicates that additional, endogenous factors are regulating these AU-rich sites in 293 cells, though Western analyses confirmed that ZFP36 paralogs are undetectable ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). In addition, ZFP36 over-expression exerted \~2 fold repression of Δ-UTR constructs, which may indicate incomplete ablation of binding or secondary effects of ZFP36 over-expression. However, repression of WT-UTR constructs was consistently greater than for Δ-UTR variants, demonstrating specific ZFP36 repression of the defined binding sites. In summary, these heterologous assays independently confirmed ZFP36 regulation of CLIP-defined targets, and support specific effects of translation, in addition to RNA stability.

![ZFP36 regulates target protein levels in T cells.\
(**A**) Levels of mRNA and protein in *Zfp36* KO and WT T cells and ZFP36 CLIP tracks measured 4 hr post-activation for targets with robust 3'UTR ZFP36 binding. RNA values are mean RPKM ± S.E.M. of 4 biological replicates. Protein values are mean fluorescence intensities (MFI) ± S.E.M. for 3--4 mice per condition. (**B**) Design of GFP reporters with WT 3'UTR (WT-UTR) or one lacking the ZFP36 binding site (Δ-UTR). (**C**) WT-UTR or Δ-UTR reporters were co-transfected into 293 cells with *Zfp36* (+) or vector alone (-). 24 hr post-transfection, reporter mRNA and protein levels were measured by RT-qPCR and flow cytometry, respectively. Values are mean ± S.D. of 4 biological replicates in each condition. Data for *Ifng* reporters show one representative experiment of three performed. *Tnf and Cd69* reporters were analyzed in one experiment. Results of two-tailed t-tests: \*=p \< 0.05; \*\*=p \< 0.01; \*\*\*=p \< 0.001.](elife-33057-fig2){#fig2}

To directly test a role for ZFP36 in translational regulation in T cells, we next performed ribosome profiling of WT and *Zfp36* KO CD4 +T cells activated for 4 hr under Th1 conditions ([Figure 3A](#fig3){ref-type="fig"} and [Figure 3---figure supplement 1A](#fig3s1){ref-type="fig"}; \[[@bib22]\]). We observed robust ribosome association of *Zfp36* mRNA in WT cells that was lost completely downstream of the engineered gene disruption in *Zfp36* KO cells ([Figure 3---figure supplement 1B](#fig3s1){ref-type="fig"}), consistent with accurate identification of translating mRNAs. Globally, there was a subtle but significant shift toward greater ribosome association in *Zfp36* KO cells for mRNAs bound by ZFP36 in 3'UTR (p=1.04×10^−11^; KS) or CDS (p=1.58×10^−11^), relative to mRNAs with no ZFP36 binding ([Figure 3B](#fig3){ref-type="fig"}). These shifts mirror those for global RNA abundance, with two notable exceptions. First, mRNAs with ZFP36 binding in CDS showed a significantly larger shift in ribosome association than those with 3'UTR binding ([Figure 3B](#fig3){ref-type="fig"}). Second, in contrast to effects on RNA abundance, the top 20% most robust ZFP36 binding sites in 3'UTR showed similar effects on ribosome association to sites overall ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). Thus, ZFP36 target mRNAs show increased ribosome association in *Zfp36* KO cells.

![ZFP36 regulates target ribosome association.\
(**A**) Ribosome profiling of *Zfp36* KO and WT CD4 +T cells. (**B**) Changes in ribosome association between *Zfp36* KO and WT cells plotted as a CDF. (**C**) Change in translation efficiency (ΔTE) between *Zfp36* KO and WT was calculated as a delta between log2(KO/WT) from ribosome profiling and RNAseq datasets. The distribution of ZFP36 targets in mRNAs ranks by ΔTE is shown (left), along with normalized enrichment scores and FDRs from GSEA (right). Intron-bound mRNAs are shown as a representative gene set that show no enhanced TE in *Zfp36* KO cells. (**D**) Normalized coverage of ribosome profiling reads for *Tnf* and *Ifng* mRNAs in *Zfp36* KO and WT cells, with p-values from binomial tests. (**E**) Normalized coverage of ribosome profiling reads across all mRNAs for *Zfp36* KO and WT cells. Ribosome profiling data are a compilation of two experiments, with four total biological replicates per conditions.](elife-33057-fig3){#fig3}

Levels of ribosome-associated mRNA are related to total abundance. To evaluate changes in translational efficiency (ΔTE) in *Zfp36* KO versus WT T cells, ribosome profiling fold-changes were normalized to those from RNAseq. We then used Gene Set Enrichment Analysis (GSEA) to examine the distribution of ZFP36 targets among all detected mRNAs ranked by ΔTE ([@bib47]). Importantly, this analysis compares the observed ΔTE of CLIP-defined ZFP36 target mRNAs to mRNAs with no detected ZFP36 binding sites. ZFP36 3'UTR and, more significantly, CDS binding targets were strongly enriched for increased TE in *Zfp36* KO cells ([Figure 3C](#fig3){ref-type="fig"}). In addition, ZFP36 targets with highly robust 3'UTR binding showed more significant effects on TE than ZFP36 3'UTR targets overall. This enrichment was not observed for mRNAs with intronic binding sites, indicating specificity for 3'UTR and CDS binding. As a striking confirmation of these results, normalized ribosome coverage on robust 3'UTR targets *Tnf* and *Ifng* was significantly higher in *Zfp36* KO cells than WT ([Figure 3D](#fig3){ref-type="fig"}), despite no detectable difference in overall mRNA abundance ([Figure 2A](#fig2){ref-type="fig"}). Crucially, ribosome coverage averaged across all mRNAs was not appreciably different between KO and WT cells, indicating specific effects on ZFP36 targets ([Figure 3E](#fig3){ref-type="fig"}). Notably, the pattern of ribosome association along these and other transcripts is remarkably consistent between WT and *Zfp36 KO* cells, but with altered magnitude. Mechanistically, this observation indicates that ZFP36 prevents association of mRNAs with ribosomes, but does not impact elongation. These results indicate repression of mRNA target translation by ZFP36 during T- cell activation, likely at the level of initiation.

ZFP36 negatively regulates T-cell activation kinetics {#s2-4}
-----------------------------------------------------

ZFP36 target mRNAs pointed to multilayered control of T cell function, including its reported regulation of effector cytokines (e.g. *Il2, Ifng*, *Tnf*, *Il4, Il10*; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). Novel targets spanned direct components of the TCR complex (e.g. *CD3d*, *CD3e*), co-stimulatory and co-inhibitory molecules (e.g. *Cd28*, *Icos, Ctla4*), TCR-proximal signaling (*Fyn*, *Sos1*, *Akt1*), and transcriptional response (e.g. *Fos*, *Nfatc1*, *Nfkb1*). As an unbiased assessment, we examined the distribution of ZFP36 targets in high-resolution gene expression time courses of CD4 + T-cell activation ([@bib59]). ZFP36 targets were enriched for mRNAs, like its own, that were rapidly induced after T-cell activation, and targets were depleted among mRNAs with stable expression or delayed induction ([Figure 4A](#fig4){ref-type="fig"}). Gene Ontology (GO) enrichments spanned many basic metabolic and gene regulatory functions, in addition to signal transduction, cellular proliferation, and apoptosis ([Figure 4B](#fig4){ref-type="fig"}; [Supplementary file 2](#supp2){ref-type="supplementary-material"}).

![ZFP36 regulates T-cell activation kinetics.\
(**A**) Gene expression patterns from a T-cell activation time course ([@bib59]) were partitioned by k-means, and enrichment of ZFP36 3'UTR and CDS targets was determined across clusters (Fisher's Exact Test). Mean expression of genes in the three clusters most enriched (left) or depleted (right) for ZFP36 targets is plotted. (**B**) Enriched GO terms among ZFP36 HITS-CLIP targets (full results in [Supplementary File 2](#supp2){ref-type="supplementary-material"}). (**C**) Proliferation of naïve CD4 +*Zfp36* KO and WT T cells in the indicated time windows after activation, measured by ^3^H-thymidine incorporation (**D**) Fractions of apoptotic annexin-V+ and (**E**) proliferating Ki67 +CD4+T cells 24 hr post-activation. Mean ± S.E.M. is shown; circles are individual mice (n = 3--4 per genotype). (**F**) Proliferation of BG2 TCR-transgenic CD4 +T cells cultured with DCs pulsed with cognate (β-gal) or irrelevant (OVA) peptide. Mean ± S.E.M. is shown (n = 5 mice per genotype). (**G**) Proliferation of CD4 +T cells co-cultured with syngeneic (C57BL6/J) or allogeneic (Balb-c) DCs. Mean ± S.E.M. of three replicate cultures is shown. (**H**) Levels of CD69 and CD25 after activation of *Zfp36* KO and WT naïve CD4 +T cells. Mean ± S.E.M. is shown (n = 3--4 mice per genotype). (**I**) Naïve and effector subsets 40 hr post-activation in *Zfp36* KO and WT CD4 +T cells. Representative plots are shown (top), along with mean ± S.E.M and circles for individual mice (n = 4 per genotype). For (**C--I**), results of two-tailed t-tests: \*=p \< 0.05; \*\*=p \< 0.01; \*\*\*=p \< 0.001. Data are representative of three (**H**) or two (**C--G, I**) independent experiments.](elife-33057-fig4){#fig4}

Functional clustering of ZFP36 targets in proliferation and apoptosis prompted us to investigate potential regulation of T cell proliferation. In thymidine incorporation assays, naïve *Zfp36* KO CD4 +T cells showed greater proliferation than WT from 16 to 24 hr post-activation ([Figure 4C](#fig4){ref-type="fig"}). Similar results were obtained with CD8 +T cells ([Figure 4---figure supplement 2A](#fig4s2){ref-type="fig"}). This increase reflected decreased apoptosis ([Figure 4D](#fig4){ref-type="fig"}) and increased numbers of proliferating cells ([Figure 4E](#fig4){ref-type="fig"}) in KO versus WT cultures. We examined whether an action on IL-2 might account for enhanced proliferation, as increased IL-2 production in *Zfp36* KO T cells has been reported ([@bib34]), and our HITS-CLIP data confirmed direct interaction. *Zfp36* KO T cells proliferated more than WT both in the presence of excess recombinant IL-2 or neutralizing anti-IL-2 antibody, as well as in different Th polarizing conditions, indicating the effect is not solely IL-2-dependent ([Figure 4---figure supplement 2B--C](#fig4s2){ref-type="fig"}). In summary, T cells from *Zfp36* KO mice show enhanced proliferation shortly after activation under all conditions examined.

Anti-CD3 is not a physiologic stimulation, so we next examined proliferative responses to MHC-peptide-mediated TCR binding. First, we bred WT and *Zfp36* KO mice with a transgenic, class-II restricted TCR specific for a β-galactosidase-derived antigen (BG2). BG2 transgenic *Zfp36* KO cells showed greater proliferation than WT across a broad titration of cognate peptide, but not irrelevant peptide ([Figure 4F](#fig4){ref-type="fig"}). Second, *Zfp36* KO T cells also showed greater proliferation than WT in response to allogeneic DCs ([Figure 4G](#fig4){ref-type="fig"}). Therefore, *Zfp36* KO cells show an exaggerated proliferative response upon MHC-peptide stimulation over a range of signal strengths.

Analysis of canonical T-cell activation markers revealed enhanced induction of CD69 and CD25 in *Zfp36* KO versus WT cells over the first 24 hr post-activation ([Figure 4H](#fig4){ref-type="fig"}). At 40 hr post-activation, a greater proportion of *Zfp36* KO versus WT had transitioned from a naïve to effector surface phenotype ([Figure 4I](#fig4){ref-type="fig"}). Notably, thymidine incorporation data showed enhanced proliferation of *Zfp36* KO cells early after activation, but similar rates in *Zfp36* KO and WT cells after 24 hr ([Figure 2C](#fig2){ref-type="fig"}). Collectively, these results show accelerated activation kinetics in the absence of ZFP36.

ZFP36 regulation of T-cell activation is cell-intrinsic {#s2-5}
-------------------------------------------------------

The accelerated activation of *Zfp36* KO T cells could in principle reflect the activity of other cell subsets or inflammatory signals in *Zfp36* KO mice. To test for a T cell-intrinsic function, we generated mixed bone marrow (BM) chimeras, allowing isolation of WT and KO T cells that develop in the same in vivo milieu ([Figure 5A](#fig5){ref-type="fig"}). Naïve *Zfp36* KO T cells sorted from chimeras showed greater proliferation than WT 24 hr post-activation, indicating cell-intrinsic effects ([Figure 5B](#fig5){ref-type="fig"}). To assess the potential impact of secreted factors, chimera-derived WT and *Zfp36* KO cells were re-mixed 1:1 ex vivo. Here, differences between *Zfp36* KO and WT cells were still significant, but blunted compared to separate cultures. This result indicates cross-regulatory effects between WT and KO cells through secreted or surface factors, but these do not fully account for the observed differences. Interestingly, the reduced proliferation of *Zfp36* KO cells in mixed ([Figure 5B](#fig5){ref-type="fig"}, right panel) versus separate (left panel) cultures indicate that WT cells can exert a restraining effect on KO cells. Thus, accelerated activation in *Zfp36* KO cells may in part reflect compromised autoregulatory and/or suppressive functions. Three days after activation, mixed cultures remained skewed in favor of *Zfp36* KO cells, again confirming accelerated expansion ([Figure 5C](#fig5){ref-type="fig"}). These results show that ZFP36 regulation of T-cell activation is cell-intrinsic, and that ZFP36 normally functions to restrain T -cell activation.

![ZFP36 regulation of T cell activation kinetics cell-intrinsic.\
(**A**) Lethally irradiated mice were reconstituted with congenically marked WT and *Zfp36* KO BM to generate mixed chimeras. 10--12 weeks after reconstitution, naïve CD4 +WT and *Zfp36* KO T cells were sorted, then activated ex vivo separately or mixed 1:1. (**B**) Proliferating Ki67 +cells were measured 24 hr after activating naïve CD4 +T cells under Th0 or Th1 conditions. (**C**) Cultures with a 1:1 starting ratio of naïve WT and *Zfp36* KO CD4 +T cells were examined 3 days post-activation. Data from one experiment of two performed are shown.](elife-33057-fig5){#fig5}

Downstream effects of ZFP36 regulation {#s2-6}
--------------------------------------

The efficient in vitro responses of *Zfp36* KO T cells suggest they are functional, but respond with altered kinetics. To examine the downstream consequences of this differential regulation, HITS-CLIP and RNAseq analyses were done in Th1-skewed CD4 +T cells 3 days after activation. ZFP36 binding site features in cells activated for 3 days were similar to ones identified at 4 hr ([Figure 6---figure supplement 1A--B](#fig6s1){ref-type="fig"}; [supplementary file 3](#supp3){ref-type="supplementary-material"}), but results from transcriptome profiling were strikingly different at these two time points ([Figure 6A](#fig6){ref-type="fig"}). First, in contrast to subtle effects observed at the 4 hr time point, many transcripts showed highly divergent expression in *Zfp36* KO versus WT T cells 3 days after activation ([Figure 6A](#fig6){ref-type="fig"}). However, these differences were not correlated to ZFP36 HITS-CLIP binding at 72 hr ([Figure 6B](#fig6){ref-type="fig"}). Thus, the absence of ZFP36 in the early phases of T -cell activation can lead to significant secondary effects downstream.

![Accelerated signs of in vitro T cell exhaustion in absence of ZFP36.\
(**A**) Log2-transformed RPKM values from *Zfp36* KO versus WT CD4 +Th1 cell RNAseq 72 hr post-activation, with red indicating differential expression (FDR \< 0.05). Lines mark 2-fold changes. RNAseq data represent one experiment with three biological replicates per condition. (**B**) Log2-transformed fold-changes (KO/WT) plotted as a CDF, for mRNAs with 3'UTR, CDS, or no significant ZFP36 HITS-CLIP. Numbers of mRNAs in each category (**n**) and p-values from KS tests are indicated. (**C**) The gene expression profile in *Zfp36* KO CD4 +T cells 72 hr post-activation was compared to reported profiles of CD4 +T cell exhaustion using GSEA. Upregulated (orange) and downregulated (gray) gene sets in exhausted T cells showed strong overlap with corresponding sets from *Zfp36* KO T cells (FDR \< 0.001, hypergeometric test). (**D**) IFN-γ and TNF-α measured by ICS 3 and 5 days after activation of naïve CD4 +T cells. (**E**) IFN-γ and TNF-α in culture supernatants 3 and 5 days after activation of naïve CD4 +T cells. (**F**) PD-1, ICOS, and LAG-3 expression 5 and 13 days after activation under Th0 or Th1 conditions. (**D--F**) show mean ± S.E.M.; circles are individual mice (n = 3--5 per genotype). (**G**) Measurements as in (**F**) for *Zfp36* KO and WT CD4 +T cells derived from mixed BM chimeras. Cells were activated under Th1 conditions for 13 days, either separately or mixed 1:1. For (**D--G**), one representative experiment of two performed is shown. Results of two-tailed t-tests: \*=p \< 0.05; \*\*=p \< 0.01; \*\*\*=p \< 0.001; \*\*\*\*=p \< 0.0001.](elife-33057-fig6){#fig6}

GSEA with RNAseq data from Th1 *Zfp36* KO cells 3 days post-activation showed reduced activity of transcription factors driving proliferation (e.g. Myc and E2F; [Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}) and strong overlap with previously described signatures of T cell exhaustion ([Figure 6C](#fig6){ref-type="fig"}; \[[@bib11]\]). Consistent with a late activated and exhausted phenotype in *Zfp36* KO cells, the enhanced production of IFN-γ at early time points ([Figures 2A](#fig2){ref-type="fig"} and [3D](#fig3){ref-type="fig"}) gave way to comparable production by day three and reduced production by day 5 ([Figure 6D](#fig6){ref-type="fig"}). Moreover, TNF-α production was not significantly different 3 or 5 days post-activation ([Figure 6D](#fig6){ref-type="fig"}), despite large differences early on ([Figures 2A](#fig2){ref-type="fig"} and [3D](#fig3){ref-type="fig"}). In summary, relieved translational control drives elevated cytokine production in *Zfp36* KO cells early post-activation, but enhanced production dissipates downstream due to more rapid expansion and exhaustion. The net result, reflecting both dysregulated cytokine production and more rapid culture expansion ([Figures 4](#fig4){ref-type="fig"} and [5](#fig5){ref-type="fig"}), is a higher accumulation of IFN-γ and TNF-αin *Zfp36* KO culture supernatants 72 hr post-activation ([Figure 6E](#fig6){ref-type="fig"}).

We examined co-inhibitory and co-stimulatory checkpoint proteins that are linked to T cell exhaustion, and found elevated expression of PD-1 and ICOS at late time points in *Zfp36* KO cells, and more rapid peaking of LAG-3 ([Figure 6F](#fig6){ref-type="fig"}). Interestingly, these effects were observed in Th1 but not Th0 conditions, suggesting a dependence on Th1 cytokines. To test this dependence, and to examine whether elevated receptor expression was T cell-intrinsic, we analyzed cells derived from mixed BM chimeras. This analysis confirmed differential, T cell-intrinsic expression of these receptors ([Figure 6G](#fig6){ref-type="fig"}). However, re-mixing WT and KO cells ex vivo neutralized these differences, indicating they are driven by secreted factors. We tested whether recombinant IFN-γ, supplemented at levels measured in KO cultures, could cause elevated receptor expression in WT Th1 cells, and found it promoted ICOS but not PD-1 upregulation ([Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}). These results indicate that Th1 cytokines, including but not only IFN-γ, can drive an exhaustion-like phenotype. The absence of ZFP36 promoted this phenotype in vitro, due to more rapid activation and expansion coupled with greater accumulation of Th1 cytokines.

ZFP36 regulates antiviral immunity {#s2-7}
----------------------------------

The accelerated response of *Zfp36* KO T cells, and the potential for accelerated exhaustion, led us to examine the effects of ZFP36 regulation in vivo. We first determined that naïve *Zfp36* KO mice had normal T cell levels in peripheral blood and no defects in thymocyte development ([Figure 7---figure supplement 1A--B](#fig7s1){ref-type="fig"}). Total splenocytes, including T cells, were slightly reduced in *Zfp36* KO versus WT mice ([Figure 7---figure supplement 1C](#fig7s1){ref-type="fig"}), but proportions of total CD4 + and CD8+T cells were normal ([Figure 7---figure supplement 1D](#fig7s1){ref-type="fig"}). Proportions of naïve CD4 +T cells were also normal in KO mice, and naïve CD8 +T cells only slightly decreased. ([Figure 7---figure supplement 1E](#fig7s1){ref-type="fig"}). Levels of CD25-hi CD4 +cells were not significantly different in spleens of WT and KO mice, consistent with similar levels of natural Tregs ([Figure 7---figure supplement 1F](#fig7s1){ref-type="fig"}). FoxP3 expression was not examined directly ex vivo, but in vitro induction of Tregs from naïve cells CD4 +T cells, enumerated in FoxP3-GFP mice, was not different between WT and KO ([Figure 7---figure supplement 1G](#fig7s1){ref-type="fig"}; \[[@bib18]\]).

To examine the effector T cell populations present in spleen, splenocytes were stimulated directly ex vivo with phorbol myristate acetate (PMA) and ionomycin. More CD4 + and CD8+T cells produced IFN-γin KO versus WT splenocytes, but levels of IL-4 and IL17A production were comparable ([Figure 7---figure supplement 1H](#fig7s1){ref-type="fig"}). Therefore, greater numbers of Th1 cells are present at steady state in *Zfp36* KO mice. To examine whether loss of ZFP36 causes an intrinsic disposition to the Th1 fate, skewing of sorted, naïve CD4 +T cells was examined. These analyses showed indistinguishable differentiation of Th1 and Th17 subsets ex vivo in WT and *Zfp36* KO cells ([Figure 7---figure supplement 1I](#fig7s1){ref-type="fig"}). The greater accumulation of Th1 cells in vivo may therefore reflect a response to factors not replicated in vitro, or the effects of additional cell types.

The lymphocytic choriomeningitis virus (LCMV) Armstrong strain causes an acute infection leading to massive T cell expansion and viral clearance in 8--10 days ([@bib14]). Using MHC-tetramers, we observed accelerated expansion and recession of virus-specific CD4+ ([Figure 7A](#fig7){ref-type="fig"}) and CD8+ ([Figure 7B](#fig7){ref-type="fig"}) T cells in *Zfp36* KO versus WT mice in peripheral blood. This result was confirmed in independent experiments focused on early time points post-infection (p.i.), where virus-specific T cells in *Zfp36* KO mice showed earlier expansion and more rapid upregulation of CD69 ([Figure 7C--D](#fig7){ref-type="fig"}). Enumeration of virus-specific T cells in spleen mirrored dynamics in blood; levels were greater in *Zfp36* KO animals 6 days p.i., but marginally lower by day 10, consistent with more rapid expansion and resolution ([Figure 7E--F](#fig7){ref-type="fig"}). Levels of memory T cells day 40 p.i. were similar in *Zfp36* KO and WT mice. In summary, antigen-specific T cell response is clinically functional but accelerated in *Zfp36* KO mice during viral infection.

![ZFP36 regulates anti-viral immunity.\
(**A**) Virus-specific CD4 + or (**B**) CD8 +T cells were tracked in peripheral blood using MHC-tetramers after LCMV Armstrong infection (n = 8--9 mice per genotype). (**C**) Virus-specific CD4 +T cells and CD69 expression on CD4 +T cells in peripheral blood at early time points post-infection (p.i.) (n = 7--8 mice per genotype). (**D**) Virus-specific CD8 +T cells and CD69 expression on CD8 +T cells in peripheral blood at early time points p.i. (n = 7--8 mice per genotype). (**E**) Virus-specific CD4 +and (**F**) CD8 +T cells in spleen after LCMV infection (n = 5--8 mice per genotype). (**G**) Fraction of CD4 +T cells producing IFN-γ and TNF-α in splenic CD4 +T cells 6 days p.i., after ex vivo stimulation with GP66-77 peptide (n = 7--8 mice per genotype). (**H**) Levels of IFN-γ and TNF-α(gated on cytokine-producing CD4 +cells) 6 days p.i. after ex vivo stimulation with GP66-77 (n = 7--8 mice per genotype). (**I**) Raw percentage of bifunctional IFN-γ+TNF-α+CD4+cells in spleen 6 days p.i. after ex vivo stimulation with GP66-77 (left), or normalized to percentage of GP66-77 tetramer +cells (n = 7--8 mice per genotype). (**J**) Levels of LCMV genomic RNA in spleen measured by RT-qPCR (n = 9--14 per group). For (**A--J**), mean values ± S.E.M. are shown, with circles as individual mice. Results of two-tailed t-tests: \*=p \< 0.05; \*\*=p \< 0.01; \*\*\*=p \< 0.001; \*\*\*\*=p \< 0.0001. In each panel, one representative experiment of two is shown.](elife-33057-fig7){#fig7}

Stimulation with LCMV peptides ex vivo revealed higher rates of IFN-γ and TNF-αproduction in *Zfp36* KO versus WT CD4+ ([Figure 7G](#fig7){ref-type="fig"}) and CD8 +T cells 6 days p.i. ([Figure 7---figure supplement 2A](#fig7s2){ref-type="fig"}). Numbers of cytokine-producing cells were proportional to LCMV-specific tetramer +cells ([Figure 7E--F](#fig7){ref-type="fig"}). However, levels of IFN-γand TNF-α protein were significantly greater in CD4 +*Zfp36* KO cytokine-producing cells versus WT ([Figure 7H](#fig7){ref-type="fig"}), and TNF-α levels were also higher for CD8 +cells ([Figure 7---figure supplement 2B](#fig7s2){ref-type="fig"}). In addition, 'bifunctional' IFN-γ+TNF-α+T cells were more frequent in *Zfp36* KO mice, even when normalized to frequencies of tetramer +cells ([Figure 7I](#fig7){ref-type="fig"} and [Figure 7---figure supplement 3C](#fig7s3){ref-type="fig"}).

Strikingly, LCMV genomic RNA in spleen was \~10 fold lower day 6 p.i. in *Zfp36* KO versus WT animals, consistent with more rapid clearance of LCMV infection ([Figure 7J](#fig7){ref-type="fig"}). Viral load correlated inversely with levels of tetramer +CD4+ and CD8+T cells in both *Zfp36* KO and WT mice, consistent with the established role of T cell response in LCMV clearance ([Figure 7---figure supplement 2D](#fig7s2){ref-type="fig"}). To examine whether the accelerated LCMV-specific T cell response in *Zfp36* KO mice may be T cell-intrinsic, infections were repeated in mixed BM chimeras. Irradiated recipient mice were re-constituted with a 1:1 mix of congenically marked WT or *Zfp36* KO BM cells ([Figure 7---figure supplement 3A](#fig7s3){ref-type="fig"}). Ten weeks after re-constitution, pre-infection baseline measurements showed a significantly greater expansion of *Zfp36* KO T cells versus WT in blood ([Figure 7---figure supplement 3B](#fig7s3){ref-type="fig"}). However, the kinetics of WT and KO T cell response in these animals upon LCMV infection were indistinguishable ([Figure 7---figure supplement 3C--D](#fig7s3){ref-type="fig"}). Therefore, in a mixed environment in vivo, *Zfp36* KO and WT T cells show similar kinetics upon viral challenge. Notably, maximum T cell expansion was observed in mixed chimeras 7--8 days p.i., which was intermediate to the maxima observed in *Zfp36* KO (6 days) and WT (10 days) mice.

Collectively, these data demonstrate a remarkable enhancement of anti-viral immunity in the setting of reduced ZFP36 family activity in vivo. This enhancement was marked by an accelerated T cell response and enhanced production of effector cytokines and, based on mixed chimera experiments, may involve immune cell types in addition to T cells.

Discussion {#s3}
==========

Immune response requires rapid, adaptable gene regulation---features uniquely suited to post-transcriptional control. Our studies illuminate a role for ZFP36 RNA binding proteins in controlling the pace of T cell response, a crucial dimension of adaptive immunity, and tie this to the effectiveness of anti-viral responses in vivo.

ZFP36 and ZFP36L1 expression are rapidly induced upon T-cell activation, and gradually recede thereafter. While transcriptional induction has been previously established, our detection of *Zfp36* and *Zfp36l1* mRNAs in naïve T cells, in the absence of detectable protein, indicates post-transcriptional regulation of their mRNAs in T cells. Moreover, paralog auto- and cross-regulation are likely, as *Zfp36* and *Zfp36l1* mRNA 3'UTRs possess robust HITS-CLIP binding sites. We did not detect ZFP36L2 in any of our analyses, indicating it is absent or negligibly expressed under conditions examined here. However, the presence of its mRNA further suggests post-transcriptional control of ZFP36 paralog expression, and is consistent with functions in other contexts or stages of T cell function (\[[@bib55]; [@bib20]\]).

Definitive determination of ZFP36 targets in T cells by HITS-CLIP, coupled with transcriptome and ribosome profiling studies, revealed that ZFP36 attenuates T-cell activation by suppressing the abundance and translation of its mRNA targets. The correlation of ZFP36 binding with reduced mRNA abundance is consistent with reports that ZFP36 can destabilize target mRNAs by recruiting degradation factors ([@bib15]; [@bib30]). However, our ability to stratify the relative magnitude of ZFP36 binding using CLIP resolved a more complex trend, with highly robust 3'UTR binding sites (top 20%) showing no detectable correlation with RNA abundance ([Figure 1---figure supplement 3C](#fig1s3){ref-type="fig"}). This non-uniform trend was observed for 3'UTR but not CDS targets, and affected mRNA abundance but not ribosome association. Importantly, effects on protein levels in the absence of changes in mRNA abundance were confirmed independently for robust 3'UTR binding targets *Tnf*, *Ifng*, and *Cd69*. It is possible that different degrees of ZFP36 association in vivo elicit distinct functional outcomes, through differential RNP localization or downstream effector recruitment. Notably, ZPF36 CLIP showed a broad MW range of ZFP36-RNA complexes with distinct biochemical properties including stability to heat, detergent, and high salt. While the current studies did not uncover distinct mRNA targets across this range, more detailed biochemical studies will be necessary to clarify potentially distinct ZFP36 complexes in vivo, and their potentially distinct roles in different cell types of the immune system.

We further present evidence that ZFP36 suppresses translation of its target mRNAs in T cells. Endogenous targets and exogenous reporters showed greater ZFP36-dependent suppression of protein versus RNA levels ([Figure 2](#fig2){ref-type="fig"}), and ribosome profiling in primary T cells confirmed direct effects on translation ([@bib48]; [@bib37]). The strongest effects were linked to a novel class of AREs in coding sequence, uncovered with ZFP36 binding maps. CDS sites correlated with repressed RNA abundance and translation, but a greater level of repression was evident in ribosome association ([Figure 3B--D](#fig3){ref-type="fig"}). Intriguingly, some ZFP36 CLIP reads in CDS sites spanned exon-intron boundaries, indicating these associations can form prior to pre-mRNA splicing in the nucleus ([Figure 1---figure supplement 2E](#fig1s2){ref-type="fig"}). The identification of AREs in the CDS and the possibility of resulting translation control pre-programmed in the nucleus point to novel, unexplored regulatory strategies. Notably, these results differ significantly from iCLIP analyses in macrophages using exogenous GFP-tagged ZFP36, where only 3'-UTR sites correlated with target repression, and only for a ZFP36 construct with mutated MK2 phosphorylation sites ([@bib51]). In those studies, the WT ZFP36 construct showed negligible repressive effects, contrasting with our data in 293 and T cells, and data from other contexts ([@bib48]; [@bib35]). However, iCLIP data for the transduced WT ZFP36 showed low 3'UTR binding (23%), high intergenic binding (38%), and a preference for GU-rich motifs, diverging sharply from our analysis of endogenous ZFP36 and prior in vivo and in vitro characterizations ([@bib4]; [@bib58]). These differences may reflect distinct ZFP36 phosphorylation, and hence regulatory outcomes, or as yet undefined variables related to the different cellular context. A direct comparison is further confounded by the use of exogenous, transduced constructs in macrophage experiments, in contrast to our analysis of endogenous proteins in T cells. Importantly, the methods and reagents developed here allow for systematic analysis of endogenous ZFP36 proteins in future global and cell-type-specific investigations addressing these issues.

The similarity of RNA-binding maps covering both ZFP36 and ZFP36L1 (WT cells) or ZFP36L1 alone (*Zfp36* KO cells) supports redundancy of ZFP36 paralogs, a likely source of robustness in immune regulation. *Zfp36* KO cells are thus likely a partial loss-of-function due to robust ZFP36L1 expression, a notion consistent with the relatively subtle regulatory effects on RNA abundance and translation. Phenotypically, loss of *Zfp36* led to accelerated activation of mature T cells, but not uncontrolled proliferation or impaired development, which may again may reflect a partial loss of pan ZFP36 activity. Indeed, a prior study reported no effects when *Zfp36l1* was deleted in T cells, but drastic dysregulation of thymocyte proliferation upon loss of both *Zfp36l1 and Zfp36l2* ([@bib20]). These studies indicate total paralog dosage is critical, but also suggest the importance of the specific balance of ZFP36 paralogs in a defined context. Improved cell profiling methods, such as cell-type-specific tagging of RBPs, may illuminate these complexities in future studies.

The mRNA targets defined by ZFP36 HITS-CLIP span from surface molecules engaged in the earliest steps in T-cell activation to downstream signaling and transcriptional effectors. Targets were strongly enriched for regulation of proliferation and apoptosis, extending prior reports that the ZPF36 family regulates proliferation in early T- and B-cell development and cancer. In each case, the reported mechanism was distinct, spanning regulation of Notch, G1/S phase transition, and Myc, respectively ([@bib16]; [@bib20]; [@bib41]). ZFP36 HITS-CLIP identified all of these target pathways in T cells, consistent with a central function in controlling cell proliferation. However, the phenotype of *Zfp36* KO T cells is novel and distinct, leading not to uncontrolled proliferation, but to accelerated effector response and resolution. The global effects of ZFP36 repression on RNA abundance and translation were widespread but subtle, and spanned many layers of T cell function. Functional validation of novel ZFP36 targets, including T-cell activation marker *Cd69* and apoptosis regulator *Bcl2*, suggest factors that likely contribute to this regulation. Analyses with cells sorted from mixed BM chimeras showed that the enhanced activation in *Zfp36* KO cells is T cell-intrinsic ([Figure 5](#fig5){ref-type="fig"}). Experiments in which these sorted cells were re-mixed ex vivo exhibited blunted differences, as compared to cells cultured separately ([Figure 5B](#fig5){ref-type="fig"}). These results indicate a role for both intracellular and secreted factors in exerting ZFP36 regulatory effects. More broadly, the combined picture of our genomic and functional data are one of many functionally diverse targets contributing to a multifaceted, finely tuned response, which is a hallmark of post-transcriptional regulatory control.

Analyses at later time points after activation in Th1 conditions revealed widespread dysregulation of *Zfp36* KO cells, with a gene expression signature and surface phenotype resembling T cell exhaustion ([Figure 6](#fig6){ref-type="fig"}; \[[@bib11]\]). Notably, and in contrast to analyses early post-activation, changes in RNA abundance 3 days post-activation were not correlated to direct ZFP36 binding. Therefore, secondary effects of ZFP36 loss pre-dominate as T cell expansion and differentiation progress in these settings. Notably, altered expression of co-inhibitory and --stimulatory receptors in *Zfp36* KO cells was specific to Th1 cells ([Figure 6F](#fig6){ref-type="fig"}), and mixing experiments confirmed dependence on secreted factors ([Figure 6G](#fig6){ref-type="fig"}; [Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}). Thus, a dysregulated Th1 secretion profile including but not limited to elevated IFN-γ can push T cells to a state resembling exhaustion in vitro. More broadly, these results highlight the crucial point that subtle, but direct, regulation of a broad range of targets early after T-cell activation by ZFP36 can have striking downstream consequences in a rapidly expanding cell population.

In vivo studies of acute viral infection showed accelerated expansion and recession of virus-specific CD4 + and CD8+T cells in *Zfp36* KO animals. *Zfp36* KO T cells had higher levels TNF-α and IFN-γ protein expression than WT after peptide stimulation, and more 'bi-functional' TNF-α/IFN-γ co-producing cells, thought to be important for anti-viral immunity ([@bib11]). More rapid T cell expansion coincided with lower accumulated viral titers (or more rapid clearance) in *Zfp36* KO animals, indicating ZFP36 regulates anti-viral immunity. In mixed BM chimeras, the response kinetics of WT and *Zfp36* KO T cells to LCMV infection were indistinguishable. This result raises the possibility that other cell types and pathways, such as antigen presenting cells, antibody response, or innate immune regulators, could contribute to the accelerated anti-viral T cell response in *Zfp36* KO mice. It is noteworthy that the point of maximum T cell expansion in these chimeras was intermediate to that of *Zfp36* KO and WT mice. This result resembles our previous observation that WT and *Zfp36* KO cells sorted from BM chimeras show blunted differences in activation kinetics when re-mixed ex vivo, as compared to cells cultured separately ([Figure 5B](#fig5){ref-type="fig"}). Collectively, these data suggest that *Zfp36* KO and WT cells exhibit cross-regulatory effects in a mixed environment that may obscure or complement cell-intrinsic differences. Given that many prominent ZFP36 targets encode secreted factors, such cross-regulatory effects are a virtual certainty.

Collectively, these in vivo studies demonstrate an accelerated T cell response to viral infection in the absence of ZFP36, which may reflect the heightened activity of multiple cell types in addition to T cells. Regardless of the initiating mechanism, the observation of enhanced LCMV clearance is likely T cell-dependent, given the central role of T cells in LCMV immunity ([@bib31]). Accordingly, we observed a quantitative, negative correlation between viral load and antigen-specific T cell levels in vivo ([Figure 7---figure supplement 2D](#fig7s2){ref-type="fig"}). Importantly, the enhanced anti-viral response in the chronic absence of ZFP36 in KO mice is accompanied by spontaneous inflammation and autoimmunity that worsen with age. Our results starkly illustrate the delicate balance of protective immunity against destructive inflammation, and reveal post-transcriptional regulation by RBPs as central to this trade-off.

Starting from transcriptome-wide RNA binding maps in T cells, we uncovered a crucial function for ZFP36 proteins in regulating adaptive immunity. These data suggest carefully titrated inhibition of ZFP36 might serve as a pharmacologic strategy in contexts where accelerated T cell response to challenge is desirable. Our in vivo LCMV studies demonstrate acute viral infection as one context, but application to other intracellular pathogens warrants investigation. Moreover, the ability to activate T cells to target tumor antigens and the clinical utility of checkpoint inhibitors raise the possibility of exploring ZFP36 inhibition to enhance tumor immunity. ZPF36 HITS-CLIP identified many targets central to these strategies, including *Cd274* (PD-L1), *Pdcd1l2* (PD-L2), *Icos*, *Cd27*, *Cd28, Ctla-4*, *Btla,* and *Lag3*, suggesting a means for concerted regulation. The autoimmune phenotype of the *Zfp36* KO mouse highlights an important caveat, common to parallel issues seen with clinical use of checkpoint inhibitors. The tools for cell-type-specific analysis of ZFP36, its targets, and its inhibition now exist to investigate and refine this balance.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species)\       Designation                 Source or reference       Identifiers                                                      Additional information
  or resource                                                                                                                                          
  ----------------------------- --------------------------- ------------------------- ---------------------------------------------------------------- -----------------------------------
  Gene (*Mus musculus*)         *Zfp36*                     NA                        Entrez ID: 22695                                                 

  Gene (*M. musculus*)          *Zfp36l1*                   NA                        Entrez ID: 12192                                                 

  Gene (*M. musculus*)          *Zfp36l2*                   NA                        Entrez ID: 12193                                                 

  Strain (*M. musculus*),\      C57BL6/J                    Jackson Laboratory        Stock No: 000664                                                 
  strain background\                                                                                                                                   
  (*C57BL6/J*)                                                                                                                                         

  Strain (*M. musculus*),\      ZFP36 KO                    PMID:8630730                                                                               gift from P. Blackshear
  strain background\                                                                                                                                   
  (*C57BL6/J*)                                                                                                                                         

  Strain (*M. musculus*),\      BG2                         PMID:19478869                                                                              gift from N. Restifo
  strain background\                                                                                                                                   
  (*C57BL6/J*)                                                                                                                                         

  Strain (*M. musculus*),\      Thy1.1                      Jackson Laboratory        Stock No: 000406                                                 
  strain background\                                                                                                                                   
  (*C57BL6/J*)                                                                                                                                         

  Strain (*M. musculus*),\      CD45.1                      Jackson Laboratory        Stock No: 002014                                                 
  strain background\                                                                                                                                   
  (*C57BL6/J*)                                                                                                                                         

  Strain (*M. musculus*),\      FoxP3-EGFP                  Jackson Laboratory        Stock No: 006769                                                 
  strain background\                                                                                                                                   
  (*C57BL6/J*)                                                                                                                                         

  Strain (*Lymphocytic*\        LCMV Arm                    PMID:6875516                                                                               
  *Choriomeningitis Virus,*\                                                                                                                           
  *LCMV*), strain background\                                                                                                                          
  (*Armstrong*)                                                                                                                                        

  Cell line (*Homo sapien*)     293 T-rex                   Life Technologies         Cat\# R71007                                                     

  Cell line (*H. sapien*)       293T                        ATCC                      ATCC Cat\# CRL-3216,\                                            
                                                                                      RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)       

  Cell line (*M. musculus*)     J558L/GM-CSF                PMID:1460426                                                                               

  Transfected construct\        pOZ-N-FH-ZFP36              This study                                                                                 mouse *Zfp36* ORF in\
  (*M. musculus*)                                                                                                                                      pOZ-N vector

  Transfected construct\        pOZ-N-FH-ZFP36L1            This study                                                                                 mouse *Zfp36l1* ORF in\
  (*M. musculus*)                                                                                                                                      pOZ-N vector

  Transfected construct\        pOZ-N-FH-ZFP36L2            This study                                                                                 mouse *Zfp36l2* ORF in\
  (*M. musculus*)                                                                                                                                      pOZ-N vector

  Transfected construct         pOZ-N-FH vector             PMID:14712665                                                                              

  Transfected construct         pcDNA3.1(+)                 Life Technologies         Cat\# V79020                                                     

  Transfected construct         pcDNA3.1(+)-Acgfp1-\        This paper                                                                                 Acgfp1 with mouse *Ifng*\
                                IFNG-WT-UTR                                                                                                            3\'UTR

  Transfected construct         pcDNA3.1(+)-Acgfp1-\        This paper                                                                                 Acgfp1 with mouse *Ifng*\
                                IFNG-WT-UTR                                                                                                            3\'UTR with *Zfp36* binding\
                                                                                                                                                       site deleted

  Transfected construct         pcDNA5/FRT/TO               Life Technologies         Cat\# V652020                                                    

  Transfected construct         pcDNA5/FRT/TO/\             This paper                                                                                 Acgfp1 with mouse *Tnf* 3\'UTR
                                Acgfp1-TNF-WT-UTR                                                                                                      

  Transfected construct         pcDNA5/FRT/TO/\             This paper                                                                                 Acgfp1 with mouse *Tnf* 3\'UTR\
                                Acgfp1-TNF-Δ-UTR                                                                                                       with *Zfp36* binding site deleted

  Transfected construct         pcDNA5/FRT/TO/\             This paper                                                                                 Acgfp1 with mouse *Cd69* 3\'UTR
                                Acgfp1-CD69-WT-UTR                                                                                                     

  Transfected construct         pcDNA5/FRT/TO/\             This paper                                                                                 Acgfp1 with mouse *Cd69* 3\'UTR\
                                Acgfp1-CD69-Δ-UTR                                                                                                      with *Zfp36* binding site deleted

  Antibody                      Rabbit anti-pan-\           This paper                Covance custom service                                           1:2000 for Western
                                ZFP36 RF2046                                                                                                           

  Antibody                      Rabbit anti-pan-\           This paper                Covance custom service                                           1:2000 for Western
                                ZFP36 RF2047                                                                                                           

  Antibody                      anti-Br-dU                  Millipore                 Millipore Cat\# MAB3222;\                                        5 μg per IP
                                                                                      RRID:[AB_11212494](https://scicrunch.org/resolver/AB_11212494)   

  Antibody                      rabbit anti-TTP/ZFP36       Sigma                     Sigma-Aldrich Cat\# T5327;\                                      1:500
                                                                                      RRID:[AB_1841222](https://scicrunch.org/resolver/AB_1841222)     

  Antibody                      rabbit anti-ZFP36L1/2\      CST                       Cell Signaling Technology\                                       1:500
                                (BRF1/2)                                              Cat\# 2119S;\                                                    
                                                                                      RRID:[AB_10695874](https://scicrunch.org/resolver/AB_10695874)   

  Antibody                      mouse anti-FLAG             Sigma                     Sigma-Aldrich Cat\# F3165;\                                      1:500
                                                                                      RRID:[AB_259529](https://scicrunch.org/resolver/AB_259529)       

  Antibody                      mouse anti-FUS              Santa Cruz                Santa Cruz Biotechnology\                                        1:1000
                                                                                      Cat\# sc-47711;\                                                 
                                                                                      RRID:[AB_2105208](https://scicrunch.org/resolver/AB_2105208)     

  Antibody                      rabbit anti-FUS             Novus                     Novus Cat\# NB100-562;\                                          1:10000
                                                                                      RRID:[AB_10002858](https://scicrunch.org/resolver/AB_10002858)   

  antibody                      goat anti-rabbit-IgG-\      LICOR                     LI-COR Biosciences\                                              1:25000
                                680RD                                                 Cat\# 925--68071;\                                               
                                                                                      RRID:[AB_2721181](https://scicrunch.org/resolver/AB_2721181)     

  Antibody                      goat anti-rabbit-IgG-\      LICOR                     LI-COR Biosciences\                                              1:25000
                                800CW                                                 Cat\# 925--32211;\                                               
                                                                                      RRID:[AB_2651127](https://scicrunch.org/resolver/AB_2651127)     

  Antibody                      goat anti-mouse-IgG-\       LICOR                     LI-COR Biosciences\                                              1:25000
                                800CW                                                 Cat\# 925--32210;\                                               
                                                                                      RRID:[AB_2687825](https://scicrunch.org/resolver/AB_2687825)     

  Antibody                      anti-CD4-PerCP-Cy5.5        BD Biosciences            BD Biosciences Cat\# 550954;\                                    1:400
                                                                                      RRID:[AB_393977](https://scicrunch.org/resolver/AB_393977)       

  Antibody                      anti-CD25-PE/Cy7            Biolegend                 BioLegend Cat\# 102016;\                                         1:400
                                                                                      RRID:[AB_312865](https://scicrunch.org/resolver/AB_312865)       

  Antibody                      anti-CD62L-APC              BD Biosciences            BD Biosciences Cat\# 561919;\                                    1:800
                                                                                      RRID:[AB_10895379](https://scicrunch.org/resolver/AB_10895379)   

  Antibody                      anti-CD44-PE                BD Biosciences            BD Biosciences Cat\# 560569;\                                    1:1000
                                                                                      RRID:[AB_1727484](https://scicrunch.org/resolver/AB_1727484)     

  Antibody                      anti-CD8-BV510              Biolegend                 BioLegend Cat\# 100752;\                                         1:400
                                                                                      RRID:[AB_2563057](https://scicrunch.org/resolver/AB_2563057)     

  Antibody                      anti-Thy1.2-BUV395          BD Biosciences            BD Biosciences Cat\# 565257                                      1:200

  Antibody                      anti-Thy1.1-FITC            Biolegend                 BioLegend Cat\# 202504;\                                         1:400
                                                                                      RRID:[AB_1595653](https://scicrunch.org/resolver/AB_1595653)     

  Antibody                      anti-CD19-eFlour780         eBiosciences              Thermo Fisher Scientific\                                        1:200
                                                                                      Cat\# 47-0193-82;\                                               
                                                                                      RRID:[AB_10853189](https://scicrunch.org/resolver/AB_10853189)   

  Antibody                      anti-CD11b-eFlour780        eBiosciences              Thermo Fisher Scientific\                                        1:200
                                                                                      Cat\# 47-0112-82;\                                               
                                                                                      RRID:[AB_1603193](https://scicrunch.org/resolver/AB_1603193)     

  Antibody                      anti-CD11c-eFlour780        eBiosciences              Thermo Fisher Scientific\                                        1:100
                                                                                      Cat\# 47-0114-80;\                                               
                                                                                      RRID:[AB_1548663](https://scicrunch.org/resolver/AB_1548663)     

  Antibody                      anti-NK1.1-eFlour780        eBiosciences              Thermo Fisher Scientific\                                        1:100
                                                                                      Cat\# 47--5941;\                                                 
                                                                                      RRID:[AB_10853969](https://scicrunch.org/resolver/AB_10853969)   

  Antibody                      anti-CD69-FITC              Biolegend                 BioLegend Cat\# 104506;\                                         1:200
                                                                                      RRID:[AB_313109](https://scicrunch.org/resolver/AB_313109)       

  Antibody                      anti-BCL2-PE/Cy7            Biolegend                 BioLegend Cat\# 633512;\                                         1:200
                                                                                      RRID:[AB_2565247](https://scicrunch.org/resolver/AB_2565247)     

  Antibody                      anti-TNF-APC/Cy7            BD Biosciences            BD Biosciences Cat\# 560658;\                                    1:200
                                                                                      RRID:[AB_1727577](https://scicrunch.org/resolver/AB_1727577)     

  Antibody                      anti-IFNG-Alexa647          BD Biosciences            BD Biosciences Cat\# 557735;\                                    1:1000
                                                                                      RRID:[AB_396843](https://scicrunch.org/resolver/AB_396843)       

  Antibody                      anti-Ki67-PE/Cy7            Biolegend                 BioLegend Cat\# 652426;\                                         1:200
                                                                                      RRID:[AB_2632694](https://scicrunch.org/resolver/AB_2632694)     

  Antibody                      anti-CD44-BUV737            BD Biosciences            BD Biosciences Cat\# 564392                                      1:400

  Antibody                      anti-PD-1-PE/Cy7            Biolegend                 BioLegend Cat\# 135216;\                                         1:200
                                                                                      RRID:[AB_10689635](https://scicrunch.org/resolver/AB_10689635)   

  Antibody                      anti-LAG3-APC               Biolegend                 BioLegend Cat\# 125210;\                                         1:200
                                                                                      RRID:[AB_10639727](https://scicrunch.org/resolver/AB_10639727)   

  Antibody                      anti-ICOS-PE                Biolegend                 BioLegend Cat\# 107706;\                                         1:200
                                                                                      RRID:[AB_313335](https://scicrunch.org/resolver/AB_313335)       

  Antibody                      anti-mouse-IL-2\            Biolegend                 BioLegend Cat\# 503705;\                                         10 μg/ml
                                (neutralizing)                                        RRID:[AB_11150768](https://scicrunch.org/resolver/AB_11150768)   

  Antibody                      anti-mouse-CD3e\            Biolegend                 BioLegend Cat\# 100314;\                                         0.25 μg/ml
                                (stim)                                                RRID:[AB_312679](https://scicrunch.org/resolver/AB_312679)       

  Antibody                      anti-mouse-CD28\            Biolegend                 BioLegend Cat\# 102112;\                                         1 μg/ml
                                (co-stim)                                             RRID:[AB_312877](https://scicrunch.org/resolver/AB_312877)       

  Other, MHC tetramer           LCMV GP33-41-specific\      MBL                       Cat\# TS-M512-1                                                  1:400
                                H-2D^b^- MHC-tetramer,\                                                                                                
                                PE conjugate                                                                                                           

  Other, MHC tetramer           LCMV GP66-77-specific\      NIH Tetramer Core\                                                                         1:300
                                I-A^b^- MHC-tetramer,\      Facility                                                                                   
                                APC conjugate                                                                                                          

  Peptide, recombinant\         LCMV GP33-41 peptide\       Life Technologies         Custom synthesis                                                 
  protein                       *KAVYNFATM*                                                                                                            

  Peptide, recombinant\         LCMV GP66-77 peptide\       Life Technologies         Custom synthesis                                                 
  protein                       DIYKGVYQFKSV                                                                                                           

  Peptide, recombinant\         Ovalbumin p257\             Life Technologies         Custom synthesis                                                 
  protein                       peptide SIINFEKL                                                                                                       

  Peptide, recombinant\         Ovalbumin p323 peptide\     Life Technologies         Custom synthesis                                                 
  protein                       ISQAVHAAHAEINEAGR                                                                                                      

  Peptide, recombinant\         Recombinant mouse\          R and D Systems           Cat\# 410-MT-050                                                 
  protein                       TNF-α                                                                                                                  

  Peptide, recombinant\         Recombinant human\          Peprotech                 Cat\# 200--02                                                    
  protein                       IL-2                                                                                                                   

  Peptide, recombinant\         Recombinant mouse\          eBiosciences              Cat\# 14-8121-80                                                 
  protein                       IL-12                                                                                                                  

  Peptide, recombinant\         Recombinant mouse\          eBiosciences              Cat\# 14-8231-63                                                 
  protein                       IL-23                                                                                                                  

  Peptide, recombinant\         Recombinant mouse\          eBiosciences              Cat\# 14--8061                                                   
  protein                       IL-6                                                                                                                   

  Peptide, recombinant\         Recombinant human\          R and D Systems           Cat\# 240-B-010                                                  
  protein                       TGF-β1                                                                                                                 

  Peptide, recombinant\         T4 Polynucleotide\          New England Biolabs       Cat\# M0201L                                                     
  protein                       Kinase                                                                                                                 

  Peptide, recombinant\         T4 RNA ligase 2,\           New England Biolabs       Cat\# M0373L                                                     
  protein                       truncated KQ                                                                                                           

  Peptide, recombinant\         CircLigase                  Epicentre                 Cat\# CL4115K                                                    
  protein                                                                                                                                              

  Peptide, recombinant\         Phusion Polymerase          New England Biolabs       Cat\# M0530L                                                     
  protein                                                                                                                                              

  Peptide, recombinant\         Micrococcal nuclease        New England Biolabs       Cat\# M0247S                                                     
  protein                                                                                                                                              

  Peptide, recombinant\         RNAsin Plus                 Promega                   Cat\# N2611                                                      
  protein                                                                                                                                              

  Peptide, recombinant\         RNAse A                     Affymetrix                Cat\# 70194Y                                                     
  protein                                                                                                                                              

  Peptide, recombinant\         RNAse I                     Thermo Fisher             Cat\# EN0601                                                     
  protein                                                                                                                                              

  Peptide, recombinant\         alkaline phosphatase        Roche                     Cat\# 10 713 023 001                                             
  protein                                                                                                                                              

  Commercial assay or\          Xtremegene 9\               Roche                     Cat\# 06 365 787 001                                             
  kit                           Transfection Reagent                                                                                                   

  Commercial assay or\          Mouse CD4\                  Miltenyi                  Cat\# 130-049-201                                                
  kit                           microbeads                                                                                                             

  Commercial assay or\          Mouse CD8\                  Miltenyi                  Cat\# 130-049-401                                                
  kit                           microbeads                                                                                                             

  Commercial assay or\          Mouse CD11c\                Miltenyi                  Cat\# 130-108-338                                                
  kit                           microbeads                                                                                                             

  Commercial assay or\          Mouse CD19\                 Miltenyi                  Cat\# 130-052-201                                                
  kit                           microbeads                                                                                                             

  Commercial assay or\          Mouse CD11b\                Miltenyi                  Cat\# 130-049-601                                                
  kit                           microbeads                                                                                                             

  Commercial assay or\          Mouse CD4 + CD62L +\        Miltenyi                  Cat\# 130-093-227                                                
  kit                           T cell isolation kit                                                                                                   

  Commercial assay or\          Trizol Reagent              Life Technologies         Cat\# 15596026                                                   
  kit                                                                                                                                                  

  Commercial assay or\          High Pure RNA\              Roche                     Cat\# 11828665001                                                
  kit                           Isolation Kit                                                                                                          

  Commercial assay or\          Truseq RNA Library\         Illumina                  Cat\# RS-122--2001                                               
  kit                           Kit                                                                                                                    

  Commercial assay or\          Ribo-Zero rRNA\             Illumina                  Cat\# MRZH11124                                                  
  kit                           removal kit                                                                                                            

  Commercial assay or\          Cytofix/Cytoperm\           BD Biosciences            Cat\# 554722                                                     
  kit                           Kit                                                                                                                    

  Commercial assay or\          Ampure XP beads             Beckman-Coulter           Cat\# A63881                                                     
  kit                                                                                                                                                  

  Commercial assay or\          Quant-IT dsDNA Assay\       Life Technologies         Cat\# Q33120                                                     
  kit                           Kit, High Sensitivity                                                                                                  

  Commercial assay or\          iQ SYBR Green SuperMix      Biorad                    Cat\# 1708880                                                    
  kit                                                                                                                                                  

  Commercial assay or\          iScript cDNA Synthesis\     Biorad                    Cat\# 1708891                                                    
  kit                           Kit                                                                                                                    

  Chemical compound,\           doxycycline                 Sigma                     Cat\# D9891                                                      
  drug                                                                                                                                                 

  Chemical compound,\           DAPI                        Sigma                     Cat\# 32670                                                      
  drug                                                                                                                                                 

  Chemical compound,\           dimethylpidilate (DMP)      Life Technologies         Cat\# 21666                                                      
  drug                                                                                                                                                 

  Chemical compound,\           5-bromo2'-deoxyuridine      Sigma                     Cat\# B9285                                                      
  drug                                                                                                                                                 

  Chemical compound,\           Denhardt's Solution (50X)   Life Technologies         Cat\# 750018                                                     
  drug                                                                                                                                                 

  Chemical compound,\           cycloheximide               Sigma                     Cat\# C104450                                                    
  drug                                                                                                                                                 

  Chemical compound,\           Ribonucleoside vanadyl\     New England Biolabs       Cat\# S1402S                                                     
  drug                          complexes (RVC)                                                                                                        

  Chemical compound,\           Live-Dead Fixable Aqua      Life Technologies         Cat\# L34957                                                     
  drug                                                                                                                                                 

  Chemical compound,\           TO-PRO-3 Iodide             Life Technologies         Cat\# T3605                                                      
  drug                                                                                                                                                 

  Software, algorithm           CLIP Toolkit (CTK)          PMID:27797762                                                                              

  Software, algorithm           STAR Aligner                PMID:23104886                                                                              

  Software, algorithm           Bowtie2                     PMID:22388286                                                                              

  Software, algorithm           HOMER                       PMID:20513432                                                                              

  Software, algorithm           GenomicRanges\              PMID:23950696                                                                              
                                (R Bioconductor)                                                                                                       

  Software, algorithm           TxDb.Mmusculus.\            DOI: 10.18129/B9.bioc.\                                                                    
                                UCSC.mm10.ensGene\          TxDb.Mmusculus.UCSC.\                                                                      
                                (R Bioconductor)            mm10.knownGene                                                                             

  Software, algorithm           TopGO (R Bioconductor)      DOI: 10.18129/B9.bioc.\                                                                    Adrian Alexa, Jorg Rahnenfuhrer
                                                            topGO                                                                                      

  Software, algorithm           edgeR (R Bioconductor)      PMID:19910308                                                                              

  Software, algorithm           HTseq                       PMID:25260700                                                                              

  Software, algorithm           Cluster 3.0                 PMID:14871861                                                                              

  Software, algorithm           Java Treeview               PMID:15180930                                                                              

  Software, algorithm           Gene Set Enrichment\        PMID:16199517                                                                              
                                Analysis (GSEA)                                                                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Data reporting {#s4-1}
--------------

All data reported are for independent biological replicates, unless specifically noted in figure legends. In most cases, one mouse was one biological replicate. For CLIP studies 2--4 littermate mice of the same sex and genotype were pooled for each biological replicate. When performed, technical replicates deriving from the same biological replicate were averaged. For ex vivo studies, including genomic analyses, a sample size of 3--5 biological replicates was judged sufficient based on a power analysis using values from pilot studies, requiring p\<0.05 with 95% power. To account for greater variability, sample sizes were doubled for in vivo studies. Mouse studies were not blinded.

Mice and cell maintenance {#s4-2}
-------------------------

### Mice {#s4-2-1}

All mouse experiments were approved by The Rockefeller University Institutional Animal Care and Use Committee regulations (Protocol 17035 hr). *Zfp36* KO mice were a generous gift from P. Blackshear (NIH; \[[@bib49]\]). BG2 mice, a TCR transgenic line specific for the class-II-restricted peptide β-gal p726 (NLSVTLPAASHAIPH) from bacterial β-galactosidase, were a generous gift from Nicolas Restifo (NIH; \[[@bib50]\]). FoxP3-EGFP mice were obtained from Jackson Laboratories ([@bib18]). Unless otherwise noted, mice of both sexes were analyzed at age 4--6, and comparisons were between littermates.

### Cell lines {#s4-2-2}

293 cell lines were maintained under standard conditions (humidified, 37°C, 5% CO~2~) in DMEM supplemented with 10% fetal bovine serum (FBS) and 0.2 mg/ml gentimicin. HEK 293T (ATCC) were authenticated by STR profiling. 293 T-rex cells were obtained directly from Life Technologies, and authenticated by functional testing of the Tet-on system. HEK cells are on the list of commonly misidentified cells lines maintained by the Internal Cell Line Authentication Committee. HEK lineage was not further confirmed here, as this was not important for these studies. J558L cells stably expressing mouse GM-CSF (a gift from Ralph Steinman; [@bib21]) were maintained under standard conditions in RPMI supplemented with 10% FBS, non-essential amino acids, and 0.2 mg/ml gentimicin (R10 media). Production of GM-CSF was confirmed by ELISA of culture supernatants. All cell lines were confirmed mycoplasma-free by the Bionique Testing Laboratories CellShipper service (Saranac Lake, NY).

### T cell cultures {#s4-2-3}

Purified T cells were cultured with BMDCs at a 30:1 ratio and 0.2 μg/ml α-CD3 (unless otherwise noted) under standard conditions in Iscove's Minimum Defined Media (IMDM) supplemented with 10% FBS, non-essential amino acids, and 0.2 mg/ml gentimicin. Cytokine conditions, unless otherwise noted, were: Th0 (10 U/ml hIL-2); Th1 (10 U/ml hIL-2 and 5 ng/ml mIL-12); Th17 (20 ng/ml mIL-6, 10 ng/ml mIL-23, 1 ng/ml hTGF-β); and iTreg (10 U/ml hIL-2 and 2.5 ng/ml hTGF-β). Media with fresh cytokines were replenished every 2--3 days.

### Bone Marrow-Derived Dendritic Cells {#s4-2-4}

Bone marrow was flushed from tibia, femur, and pelvic bones with 26.5 gauge needles, and RBCs were lysed. Cells were plated at 10^6^ per ml in (IMDM) supplemented with 10% FBS, 0.2 mg/ml gentamycin, and a 1:20 dilution of supernatant from J558L cells stably expressing recombinant GM-CSF. Cells were refreshed on days 3, 5, and 7 with 0.5 ml additional J558L/GM-CSF supernatant. At Day 7, non-adherent cells were collected and CD11c + cells positively isolated with CD11c microbeads (Miltenyi). CD11c + cells were replated in IMDM with 1:20 J558L supernatant and 50 ng/ml recombinant mouse TNF-α (R and D Systems). At Day 9, non-adherent BMDCs were collected, washed in PBS to remove cytokines, and cryopreserved in a mix of 90% FBS and 10% DMSO.

Experimental method details {#s4-3}
---------------------------

### Pan ZFP36 antisera generation {#s4-3-1}

Two pan-ZFP36 antisera (RF2046 and RF2047) were produced in rabbits by Covance against the conserved C-terminal peptide APRRLPIFNRISVSE, and successfully confirmed by ELISA, immunoblotting, and immunoprecipitation (IP). Reactivity to paralogs ZFP36, ZFP36L1, and ZFP36L2 was confirmed immunoblotting ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}) and IP (not shown).

### Plasmid construction {#s4-3-2}

ZFP36 paralog expression plasmids were generated by PCR-amplification of coding sequences from mouse spleen cDNA, and cloning into the XhoI/NotI sites of the pOZ-N vector ([@bib33]), which has a N-terminal FLAG-HA tag and a human CD25 selection marker. Reporter plasmids were generated by cloning 3'UTR sequences downstream of an Acgfp1 cDNA. *Ifng* reporters were constructed in pcDNA3.1(+) vector, and *Tnf and Cd69* reporters were constructed in the doxycycline inducible pcDNA5/FRT/TO vector (both vectors from Life Technologies). The full length 3'UTR of mouse *Ifng*, *Cd69, and Tnf* and versions with the CLIP-defined ZFP36 binding sites deleted, were synthesized as gBlocks (IDT) and inserted using EcoRV and NotI sites.

### Reporter transfection assays {#s4-3-3}

293 T-rex cells were maintained under standard conditions with DMEM supplemented with 10% FBS and gentamycin, in the presence of 100 ng/ml doxycycline to induce reporter expression. Cells were transfected with Xtremegene9 reagent, using a 3:1 reagent:plasmid ratio and 250 ng total DNA per well in a 24-well dish. Reporter plasmids were co-transfected with pOZ-N-mZFP36 (or empty pOZ-N vector) at a 1:1 ratio (125 ng each). 30 hr post-transfection, cells were harvested in PBS/5 mM EDTA, stained with anti-human-CD25-PE to identify pOZ-N-transfected cells, and analyzed for GFP expression by flow cytometry on the Miltenyi MACSQuant or FACSCalibur. DAPI (20 ng/ml) or TO-PRO-3 (0.1 μM; Life Technologies) were added to acquisition buffer for dead-cell exclusion. Reported MFI values are for GFP in live, CD25 +cells. RNA was harvested from replicate plates by Trizol extraction followed by cleanup, with DNAse treatment, on HiPure columns (Roche). GFP mRNA was quantified by RT-qPCR using GFP-specific primers and human GADPH primers as a reference control.

### T-cell purification {#s4-3-4}

For purification of pan-CD4 +and CD8+T cells, splenocytes were cleared of RBCs by hypotonic lysis, and DC populations were depleted with CD11c microbeads (Miltenyi Biotec). T cells were then purified with CD4 or CD8 microbeads.

CD4 +naïve T cells were purified by two strategies. In most experiments, CD4 +cells were pre-enriched from pooled splenocytes and lymph nodes (LNs) by positive selection with CD4 microbeads or depletion with CD19, CD11b, and CD8 microbeads. Naïve CD4 +CD25 CD44-loCD62L-hi cells were then FACS-sorted to \>99% purity. In ribosome profiling experiments and for western blot time courses ([Figure 1A](#fig1){ref-type="fig"}), naïve CD4 +cells were purified to \>95% purity with the CD4 +CD62L + isolation kit (Miltenyi).

### T-cell treatment for RNAseq, HITS-CLIP, and ribosome profiling {#s4-3-5}

For RNAseq, HITS-CLIP and ribosome profiling experiments, selective recovery of T cell RNA from T cell/DC co-cultures was achieved by using formalin-fixed DCs for co-stimulation. BMDCs were fixed prior to co-culture setup in 1% paraformaldehyde (in 1X PBS) for 5 min at room temperature, quenched with a 5-fold volume 0.4M lysine prepared in 1X PBS/5% FBS, and washed extensively in PBS/5% FBS. Pilot experiments confirmed that fixed DCs provide co-stimulatory signals to T cells and induce ZFP36 expression, though at approximately 2-fold lower efficiency than live DCs (not shown). Thus, a 15:1 T cell:DC ratio was used with fixed DCs. RT-qPCR measurements confirmed that fixation quenched recovery of DC RNA by \~100 fold (not shown), ensuring selective recovery of T cell RNA. DC-only RNAseq control samples confirmed that recovered reads from DC RNA were negligible (not shown).

### Immunoblotting {#s4-3-6}

Cell lysates were prepared in lysis buffer \[1X PBS/1% Igepal/0.5% sodium deoxycholate (DOC)/0.1% SDS supplemented with complete protease inhibitors and Halt phosphatase inhibitors (Roche)\]. Protein concentrations were determined by Bradford assay (Biorad), and 10 μg total protein per sample were run on NuPAGE gels (Life Technologies) and transferred to fluorescence-compatible PVDF membrane (Millipore). Membranes were blocked in Odyssey PBS-based buffer (LICOR) for 1 hr to overnight, then primary antibodies were added for 1 hr at room temperature. Antibodies used for western blotting were: TTP (Sigma T5327, 1:500); ZFP36L1 (CST 2119S, 1:500); FUS (Santa Cruz sc-47711, 1:1000; or Novus NB100-562, 1:10000). After 3 washes in 1X PBS/0.05% Tween-20, membranes were incubated with fluorescent secondary antibodies (LICOR, 1:25,000) for 1 hr at room temperature. Membranes were washed 3 times in 1X PBS/0.05% Tween-20, rinsed in 1X PBS, and visualized on the Odyssey Imaging system (LICOR).

ZFP36 HITS-CLIP {#s4-4}
---------------

### Cell preparation and UV Cross-linking {#s4-4-1}

FACS-sorted CD4 +naïve T cells were activated as described above in the presence of formalin-fixed DCs. Cells were harvested at 4 hr, or at 72 hr with 2 hr PMA/ionomycin re-stimulation. Harvested cells were UV-irradiated once at 400 mJ/cm^2^ and once at 200 mJ/cm^2^ in ice cold 1X PBS, pelleted, and snap-frozen until use.

#### Bead preparation {#s4-4-1-1}

ZFP36 antisera or control sera from pre-immune rabbits was conjugated to Protein A Dynabeads (Life Technologies) in binding buffer (0.1 M Na-Phosphate, pH 8.0), and washed three times to remove unbound material. IgG was covalently cross-linked to beads with 25 mM dimethylpidilate (DMP) in 0.2 M triethanolamine (pH 8.2) for 45 min at room temperature. Beads were washed twice in 0.2 M ethanolamine pH 8.0, then washed several times in PBS/0.02% Tween-20 containing 5X Denhardt's buffer. Beads were blocked overnight in the final wash prior to use.

#### Lysis and immunoprecipitation {#s4-4-1-2}

Cell pellets were re-suspended in 250 μl lysis buffer \[1X PBS/1% Igepal/0.5% sodium deoxycholate (DOC)/0.1% SDS supplemented with cOmplete protease inhibitors (Roche), 10 mM ribonucleoside vanadyl complexes (RVC)\]. 5 μl RQ1 DNAse (Promega) was added and incubated 5 min at 37°C with intermittent shaking. For partial digestion, NaOH was added to lysates to 50 mM and incubated at 37°C with shaking for 10 min. Alkali was neutralized by addition of equimolar HCl and HEPES pH 7.3 to 10 mM, and SuperRNAsin (Roche) was added to 0.5 U/μl. For over-digested samples, RVC was omitted from lysate preparation, and RNAse A (1:1000, USB) and RNAse I (1:100, Thermo Fisher) were added and incubated at 37°C for 5 min. Lysates were cleared by centrifugation (14,000 rpm for 10 min), and rocked with beads for 45 min to 1 hr at 4°C. Beads were washed:

-   Twice lysis buffer containing 5X Denhardt's Solution

-   Twice high detergent buffer (1X PBS/1% Igepal/1% DOC/0.2% SDS).

-   Twice high-salt buffer (1X PBS/1% Igepal/0.5% DOC/0.1% SDS, 1M NaCl \[final, including PBS\])

-   Three times low salt buffer (15 mM Tris pH 7.5, 5 mM EDTA)

-   Twice PNK wash buffer (50 mM Tris pH 7.5, 10 mM MgCl~2~, 0.5% Igepal)

#### Post-IP on-bead processing {#s4-4-1-3}

Alkaline phosphatase treatment, polynucleotide kinase (PNK) radiolabeling, addition of pre-adenylated 3' linker, SDS-PAGE, and nitrocellulose transfer and extraction were performed exactly as described ([@bib32]).

#### RNA footprint cloning {#s4-4-1-4}

CLIP footprints were reverse-transcribed using the Br-dU incorporation and bead-capture strategy, exactly as described ([@bib57]). Indexed reverse transcription (RT) primers were used ([Table 1](#table1){ref-type="table"}), allowing multiplexing of 8 samples per Miseq (Illumina) run. cDNA was circularized with CircLigase (Epicentre) as described ([@bib57]), then amplified with PCR primers with Illumina sequencing adapters. Amplification was tracked with SYBR green (Life Technologies) on the iQ5 Real Time Thermocycler (Biorad), and reactions were stopped once signal reached 500--1000 relative fluorescence units (r.f.u.). Products were purified with Ampure XP beads (Beckman) and quantified with the Quant-IT kit (Life Technologies) and/or Tapestation system (Agilent). Multiplexed samples were run on the Illumina Miseq with 75 base pair single-end reads.

10.7554/eLife.33057.022

###### Oligonucleotide sequences

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Primer name                        Sequence                                                                            Description
  ---------------------------------- ----------------------------------------------------------------------------------- ------------------------------
  cloning                                                                                                                

  MJM9                               ATGACTCGAGGATCTCTCTGCCATCTACGAGAGCC                                                 mouse ZFP36 forward\
                                                                                                                         XhoI primer

  MJM10                              ATGAGCGGCCGCTCACTCAGAGACAGAGATACGATTGAAGATGG                                        mouse ZFP36 reverse\
                                                                                                                         NotI primer

  MJM266                             ATGACTCGAGACCACCACCCTCGTGTCC                                                        mouse ZFP36L1 forward\
                                                                                                                         XhoI primer

  MJM267                             ATGAGCGGCCGCTTAGTCATCTGAGATGGAGAGTCTGC G                                            mouse ZFP36L1 reverse\
                                                                                                                         NotI primer

  MJM270                             ATGACTCGAGTCGACCACACTTCTGTCACCC                                                     mouse ZFP36L2 forward\
                                                                                                                         XhoI primer

  MJM271                             ATGAGCGGCCGCTCAGTCGTCGGAGATGGAGAGG                                                  mouse ZFP36L2 reverse\
                                                                                                                         NotI primer

  RT-qPCR                                                                                                                

  GP-f                               CATTCACCTGGACTTTGTCAGACTC                                                           LCMV RNA forward qPCR

  GP-r                               GCAACTGCTGTGTTCCCGAAAC                                                              LCMV RNA reverse qPCR

  MJM432                             GATTGTGGGACATCCTGGTC                                                                mouse RPL10A forward\
                                                                                                                         qPCR

  MJM433                             TCAGACCCATGACTGCTGAG                                                                mouse RPL10A reverse\
                                                                                                                         qPCR

  MJM500                             AACATCGAAGACGGCTCTGT                                                                IFNG reporter forward\
                                                                                                                         qPCR

  MJM501                             GCGCTCTGTGTGGACAAGTA                                                                IFNG reporter reverse qPCR

  MJM504                             CCACTACCTGAGCACCCAGT                                                                CD69 and TNF reporters\
                                                                                                                         forward qPCR

  MJM505                             GAACTCCAGCAGGACCATGT                                                                CD69 and TNF reporters\
                                                                                                                         reverse qPCR

  GAPDH-f                            GTCTCCTCTGACTTCAACAGCG                                                              human GAPDH forward\
                                                                                                                         qPCR

  GAPDH-r                            ACCACCCTGTTGCTGTAGCCAA                                                              human GAPDH reverse\
                                                                                                                         qPCR

  HITS-CLIP and ribosome profiling                                                                                       

  preA-L32                           /5rApp/GTGTCAGTCACTTCCAGCGG/3ddc/                                                   Pre-Adenylated 3\' ligation\
                                                                                                                         linker

  RT1                                /5Phos/DDDCGATNNNNNNNAGATCGGAAGAGCGTCGT/iSp18/CACTCA/iSp18/**CCGCTGGAAGTGACTGAC**   Indexed RT primer

  RT2                                /5Phos/DDDTAGCNNNNNNNAGATCGGAAGAGCGTCGT/iSp18/CACTCA/iSp18/**CCGCTGGAAGTGACTGAC**   Indexed RT primer

  RT3                                /5Phos/DDDATCGNNNNNNNAGATCGGAAGAGCGTCGT/iSp18/CACTCA/iSp18/**CCGCTGGAAGTGACTGAC**   Indexed RT primer

  RT4                                /5Phos/DDDGCTANNNNNNNAGATCGGAAGAGCGTCGT/iSp18/CACTCA/iSp18/**CCGCTGGAAGTGACTGAC**   Indexed RT primer

  RT5                                /5Phos/DDDCTAGNNNNNNNAGATCGGAAGAGCGTCGT/iSp18/CACTCA/iSp18/**CCGCTGGAAGTGACTGAC**   Indexed RT primer

  RT6                                /5Phos/DDDGATCNNNNNNNAGATCGGAAGAGCGTCGT/iSp18/CACTCA/iSp18/**CCGCTGGAAGTGACTGAC**   Indexed RT primer

  RT7                                /5Phos/DDDAGTCNNNNNNNAGATCGGAAGAGCGTCGT/iSp18/CACTCA/iSp18/**CCGCTGGAAGTGACTGAC**   Indexed RT primer

  RT8                                /5Phos/DDDTCGANNNNNNNAGATCGGAAGAGCGTCGT/iSp18/CACTCA/iSp18/**CCGCTGGAAGTGACTGAC**   Indexed RT primer

  DP5-PE                             AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT                          forward PCR primer,\
                                                                                                                         Illumina adapter

  SP3-PE                             CAAGCAGAAGACGGCATACGAGATCTCGGCATTCCTGCCGCTGGAAGTGACTGACAC                           reverse PCR primer,\
                                                                                                                         Illumina adapter

  PE-R1                              ACACTCTTTCCCTACACGACGCTCTTCCGATCT                                                   sequencing primer\
                                                                                                                         (standard Illumina read 1)
  -----------------------------------------------------------------------------------------------------------------------------------------------------

### RNAseq {#s4-4-2}

Total RNA was extracted Trizol (Life Technologies) and further purified, with on-column DNAse treatment, using HiPure columns (Roche). 500 ng to 1 μg total input RNA was rRNA-depleted (Ribo-Zero, Illumina), and unstranded, barcoded libraries were prepared with the TruSeq RNA library kit (Illumina). Libraries were run on the Hiseq 2000, obtaining 50 bp paired-end (PE) reads.

### Ribosome profiling {#s4-4-3}

#### Cell preparation {#s4-4-3-1}

Naïve CD4 +T cells were purified with the CD4 +CD62L + isolation kit (Miltenyi) and activated in the presence of formalin-fixed DCs, as described above. After 4 hr, 100 μg/ml cycloheximide was added to cultures and briefly incubated at 37°C. Cells were harvested on ice, washed in 1X PBS containing cycloheximide, pelleted, and snap frozen in liquid nitrogen. Four pairs of biological replicates (WT and *Zfp36* KO) were analyzed.

#### Monosome and Ribosome Protected Fragment (RPF) Preparation {#s4-4-3-2}

Cells were suspended in 0.75 ml polysome lysis buffer \[20 mM HEPES pH 7.3, 150 mM NaCl, 0.5% Igepal, 5 mM MgCl~2~, 0.5 mM DTT, complete protease inhibitors, 100 μg/ml cycloheximide, SuperRNAsin (1:1000)\]. Lysates were cleared by spinning for 10 min at 2,000 rpm to pellet nuclei, followed by 10 min at 14,000 rpm for debris. For digestion of polysomes to monosomes, 1 mM CaCl~2~ and 1500 U micrococcal nuclease (MNase, Thermo Fisher) were added to clear lysates and incubated for 45 min at room temperature with rocking. Digests were stopped with addition of 5 mM EGTA, then loaded over 10--50% w/w sucrose gradients and spun at 35,000 rpm for 3 hr. Sixteen fractions were collected using the ISCO Density Gradient Fractionation System, tracking monosome elution with UV absorbance at 254 nm.

Fractions containing monosomes and residual disomes were pooled and dialyzed against gradient buffer (20 mM HEPES pH 7.3, 150 mM NaCl, 5 mM MgCl~2~) to remove sucrose. Ribosomes were then dissociated by adding 30 mM EDTA and 0.5 M NaCl, and freed ribosome subunits were pelleted by spinning at 75,000 rpm for 2 hr. The supernatant fraction was extracted once with acid phenol and twice with chloroform, then precipitated with standard ethanol precipitation.

#### RPF cloning {#s4-4-3-3}

Pelleted RNA was re-suspended in water, and treated with PNK in the absence of ATP to remove 3' phosphates. RNA was re-precipitated in ethanol, and 3' linker addition was performed in 20 μl reactions containing 1 μM pre-adenylated L32 linker ([Table 1](#table1){ref-type="table"}), 400 U truncated RNA ligase 2 (NEB \#M0351L), and 10% polyethylene glycol (PEG MW8000) for 2 hr at room temperature. Ligation reactions were resolved on 12.5% denaturing TBE-urea PAGE gels, and RNA fragments in the range from \~50--80 nucleotides were eluted from excised polyacrylamide fragments. RPFs were ethanol-precipitated and cloned using the exact Br-dU incorporation and bead-capture method used for HITS-CLIP (see above) and described elsewhere ([@bib57]).

### Flow cytometry {#s4-4-4}

#### Surface and intracellular stains {#s4-4-4-1}

Antibodies used for flow cytometry are listed in the Key Resource Table. Flow cytometry data were acquired on the BD LSR Fortessa or LSR II systems. Cell sorting was done on the BD FACSAria. For surface stains, cells incubated with antibodies in FACS buffer (1X PBS/1% FBS) for 20 min at 4°C, then washed twice in FACS buffer. For live cell analysis, samples were then re-suspended in FACS buffer containing 20 ng/ml DAPI and acquired directly. For fixed samples, cells were washed twice with PBS after surface staining, then incubate with Live/Dead Fixable Aqua (1:1000 in PBS) for 10 min at RT. Cells were washed once with FACS buffer, then fixed and permeabilized using the BD Cytofix/CytoPerm kit. For intracellular stains, cells were then incubated with antibodies diluted in 1X Perm/Wash buffer for 30 min at RT, washed twice with Perm/Wash buffer, and acquired.

Unless noted otherwise, flow cytometry data were gated on live (DAPI- or Aqua-negative) single cells, with additional marker gates applied as indicated.

#### Intracellular cytokine staining (ICS) {#s4-4-4-2}

For ICS, cells were stimulated with PMA (20 ng/ml) and ionomycin (1 μM) for 5--6 hr in the presence of GolgiStop (BD) prior to harvesting. Cells were processed and analyzed as described above.

Cytokine production in LCMV studies was measured in response to class-I H-2^d^-restricted GP33-41 (KAVYNFATM) and class-II I-A^b^-restricted GP66-77 (DIYKGVYQFKSV) LCMV peptides. 2 × 10^6^ splenocytes were incubated in 1 ml R10 media (RPMI with 10% FBS, 50 μM β−ME, non-essential amino acids, and gentamycin) with GolgiStop and 0.2 μg/ml class-I peptides or 2 μg/ml class-II peptides. After 5--6 hr, cells were harvested and processed as described above. Gates were established using splenocytes from naïve mice and LCMV-infected mice pulsed with irrelevant peptides (class-I OVA p257 \[SIINFEKL\]; class-II OVA p323 \[ISQAVHAAHAEINEAGR\]).

#### MHC tetramers {#s4-4-4-3}

LCMV GP33*-*41*-*specific H-2D^b^-restricted MHC-tetramer was purchased as a PE conjugate from MBL. APC-conjugated LCMV GP66-77-specific I-A^b^-restricted MHC-tetramer was a kind gift from the NIH Tetramer Core Facility. For class I tetramer, staining was done as described for surface antibody staining using a 1:800 dilution in FACS buffer. For class II tetramer, staining was done at a 1:300 dilution at RT for 1 hr, then cells were washed once in FACS buffer before staining with surface antibodies as described above. In all experiments, tetramer +cell gates were established using naïve animals and irrelevant, class-matched tetramers as negative controls.

### Thymidine incorporation assays {#s4-4-5}

200 μl T cell-DC co-cultures were set up in 96-well plates, and 1 μCi ^3^H-thymidine was added at indicated time points. Cultures were harvested onto glass filter plates (Perkin-Elmer) and dried thoroughly, before addition of 30 μl scintillation fluid per well and acquisition on the Topcount scintillation counter (Perkin-Elmer).

### Apoptosis assays {#s4-4-6}

24 hr after activation, cultures were harvested on ice and stained with surface markers. Prior to acquisition, buffer was removed from samples and Annexin-V-staining buffer containing Annexin-V-PE (BD Biosciences, 2 μl per samples) and 20 ng/ml DAPI was added.

### Bone Marrow Chimeras {#s4-4-7}

Host CD45.1 mice (Jackson Laboratory 002014) were given a lethal dose of gamma radiation (900 rads), then intravenously injected with a 1:1 mix of Thy1.1 WT and Thy1.2 *Zfp36* KO BM cells (4−5 × 10^6^ total cells). Chimeras were analyzed 10--12 weeks after re-constitution.

### LCMV studies {#s4-4-8}

Mice were infected with LCMV Armstrong strain by intraperitoneal injection of 1 × 10^5^ plaque forming units. At indicated time points, peripheral blood was collected by retro-orbital bleeding and analyzed for virus-specific T cells using MHC-tetramers (see above). At 6, 10, and 40 days p.i., spleens were analyzed for LCMV-specific T cells with MHC-tetramers and analysis of cytokine production in response to LCMV peptide antigens (see above). LCMV genomic RNA was quantified in total spleen RNA by RT-qPCR. To determine copy number, a standard curve was generated using a gBlock comprising the LCMV PCR amplicon. LCMV copy number per spleen was calculated using a linear regression of the standard curve, and scaling by appropriate dilution factors.

Quantification and statistical analysis {#s4-5}
---------------------------------------

Details for statistical analysis appear in figure legends. Comparisons between experimental groups were done with two-sided student's t-tests, with p\<0.05 considered significant. Statistics for bioinformatic analyses are detailed below.

Bioinformatics {#s4-6}
--------------

### HITS-CLIP {#s4-6-1}

Processing and alignment of HITS-CLIP read data for Br-dU CLIP was done as described (\[[@bib44]; [@bib32]; [@bib57]\]). Peak calling was done with the CLIP Toolkit (CTK) command tag2peak.pl, requiring enrichment over background with FDR \< 0.01 ([@bib44]). For background determination, a genic model was used including known mouse transcripts extended 10 kb downstream to include non-annotated 3'UTR variants. For analyses in [Figure 1E--G](#fig1){ref-type="fig"} and [Figure 1---figure supplement 2C](#fig1s2){ref-type="fig"}, peaks were defined and analyzed separately for 5 WT ([Supplementary file 1A](#supp1){ref-type="supplementary-material"}) and 3 *Zfp36* KO biological replicates ([Supplementary file 1B](#supp1){ref-type="supplementary-material"}). In these analysis, bindings sites were defined as peak height \[PH\]\>5, from ≥3 biological replicates, with two different antisera. Subsequently, the 5 WT and 3 KO replicates (eight total) were pooled for peak definition to increase depth and sensitivity ([Supplementary file 1D](#supp1){ref-type="supplementary-material"}). For these analysis, peaks had to be supported by two different antisera and \>5 biological replicates, ensuring support from both WT and KO datasets. Cross-link-induced truncations (CITS) were also determined as described, pooling all biological replicates from all time points (\[[@bib44]\]; [Supplementary file 1D](#supp1){ref-type="supplementary-material"}).

Motif enrichment analysis was done on a 30 nucleotide window surrounding peaks supported in at least three biological replicates in the indicated dataset. HOMER ([@bib19]) was used with commands similar to: findMotifsGenome.pl peak_file.txt mm10 output_folder -rna -len 8

Site annotation was done with custom R scripts using the GenomicRanges and TxDb.Mmusculus.UCSC.mm10.ensGene (Transcript Database for mm10).

T cell activation time course data were downloaded from GEO, and genes were clustered by expression patterns using k means partitioning in Cluster 3.0 ([@bib12]). An optimal k of 20, as previously determined ([@bib59]), was re-confirmed by visualizing a wide range of k values in Java Treeview ([@bib42]). The distribution of ZFP36 3'UTR and CDS CLIP targets among k clustered was evaluated with Fisher's exact test. Average expression values of genes in the three most enriched and depleted clusters were plotted. Gene Ontology enrichments were determined with the TopGO package in R ([@bib1]).

### RNAseq {#s4-6-2}

RNAseq reads were aligned against the mouse reference genome (mm10) with STAR with default settings ([@bib13]). Feature counts per gene were obtained with HTSeq ([@bib2]). Differential gene expression was analyzed with edgeR using a standard t-test pipeline ([@bib40]). For CDF analysis (e.g. [Figure 1H](#fig1){ref-type="fig"}), log~2~-fold-change values derived from edgeR were plotted. Analysis included genes with average RPKM \>3 in WT or *Zfp36* KO biological replicates in RNAseq, and with sufficient coverage in ribosome profiling (see below) to permit quantification. Genes were classified based on the presence of robust ZFP36 HITS-CLIP peaks (FDR \< 0.01, supported by \>5 biological replicates) in 3'UTR or CDS. Non-exclusive site annotation was used here, meaning some genes have both 3'UTR and CDS sites. Analysis was repeated with exclusive annotation, with similar results (not shown). The negative control set was defined as genes without significant ZFP36 binding in any transcript region. Differences between gene sets were evaluated with a two-tailed Kolmogorov-Smirnov test.

The gene expression profile observed 72 hr after activation of *Zfp36* KO cells was analyzed for significantly overlapping gene sets using GSEA and the Molecular Signature Database ([@bib47]). Overlap with published profiles of CD4 +T cell exhaustion ([@bib11]) was determined with a GSEA pre-ranked analysis.

### Ribosome profiling {#s4-6-3}

Initial filtering and processing of ribosome profiling reads was done as for HITS-CLIP. Reads were aligned against a mouse reference transcriptome (Ensembl) using Bowtie 2, and read counts per transcript were calculated ([@bib26]). Differential expression analysis was done with edgeR using a paired general linear model (GLM). Only genes with cpm (counts per million read) values \> 1 in at least two biological replicates of any genotype were included. CDF analyses were done as described for RNAseq. The change in translation efficiency (ΔTE) between *Zfp36* KO and WT cells was calculated for each mRNA as the difference in log2-fold-change values (KO/WT) from ribosome profiling and RNAseq. mRNAs were ranked on the ΔTE metric, and distribution of ZFP36 CLIP targets therein was evaluated with a pre-ranked GSEA analysis.

Ribosome profiling read coverage from pooled biological replicates of each genotype was calculated across individual mRNAs with a sliding 20 nucleotide window, normalizing for dataset read depth. Differences between WT and *Zfp36* KO coverage were evaluated with a binomial test. For the metagene coverage plot, all transcripts with at least 10 reads in the region of interest were included and the proportion of reads which centered at each nucleotide position was calculated. The mean coverage for each position is shown relative to the central coding region with additional normalization included for the number of transcripts represented at each position.

Data availability {#s4-7}
-----------------

High throughput sequencing data from this study are available at the NCBI Gene Expression Omnibus (GEO) website under accession GSE96076.
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###### ZFP36 binding sites in CD4 +T cells 4 hr post-activation (attached spreadsheet).

Pan-ZFP36 HITS-CLIP peaks (A) in WT CD4 +T cells 4 hr post-activation (B) in *Zfp36* KO CD4 +T cells 4 hr post-activation. (C) identified only in *Zfp36* KO and not WT cells, and (D) pooled from WT and *Zfp36* KO samples. (E) Cross-link induced truncation (CITS) cites from all pooled ZFP36 HITS-CLIP data (FDR \< 0.01).
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###### Gene Ontology enrichments for ZFP36 target mRNAs in CD4 +T cells, 4 hr post-activation (attached spreadsheet).
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###### ZFP36 binding sites in CD4 +T cells 72 hr post-activation (attached spreadsheet).
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Data availability {#s7}
-----------------

Sequencing data are in GEO under the accession code GSE96076

The following dataset was generated:

Robert B Darnell2018ZFP36 RNA-binding proteins restrain T-cell activation and anti-viral immunity<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE96076>Publicly available at the NCBI Gene Expression Omnibus (accession no:GSE96076)

The following previously published dataset was used:

Nir Yosef2013Reconstruction of the dynamic regulatory network that controls Th17 cell differentiation by systematic perturbation in primary cells<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE43970>Publicly available at the NCBI Gene Expression Omnibus (accession no:GSE43955)
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Decision letter

Black

Douglas L

Reviewing Editor

University of California, Los Angeles

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"ZFP36 RNA-binding proteins restrain T-cell activation and anti-viral immunity\" for consideration by *eLife*. Your article has been favorably evaluated by James Manley (Senior Editor) and three reviewers, one of whom, Douglas Black, is a member of our Board of Reviewing Editors. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

Moore et al. examine the role of the ZFP36 proteins in T cell activation and immune function. This family of proteins, including *Zfp36* (also known as TTP), *Zfp36L1*, and *Zfp36L2*, are well known mediators of mRNA instability through binding to AU-rich elements (ARE). Immune cytokines such as TNF and IFNg are among their targets. The phenotype of *Zfp36* loss in mice has mainly been studied in myeloid cells but it is expected that these proteins play broader roles in immune cell function. Here the authors show that the *Zfp36* and *Zfp36L1* proteins are strongly induced by T cell activation. Using an antibody cross-reactive with all the paralogs, they perform CLIP to identify a large set of RNA binding sites across the transcriptome. They compare the binding sites of both proteins identified in WT mice with those of presumably *Zfp36L1* alone in *Zfp36* KO mice. These datasets show broad overlap, yield essentially identical binding motifs with the expected ARE, and thus the two proteins apparently bind largely the same target RNAs. The authors show that transcripts containing CLIP peaks in their 3\'UTR or CDS exhibit increased expression in the KO mice, as expected if the proteins mediate translational repression or targeted mRNA decay. Several transcripts exhibiting substantial binding of *Zfp36* in the 3\'UTR, including *Cd69* and *Tnf*, show minimal change in RNA levels in the KO but a significant increase in protein, implying an effect on translation. This is recapitulated in a reporter assay using the IFNg 3\'UTR. RNA expression from the reporter does go down in response to co-expressed *Zfp36*, but the protein product shows a larger effect. They performed ribosome profiling in WT and KO mice and correlate this with RNAseq to determine translational efficiencies. They find that transcripts with *Zfp36* binding in the 3\'UTR and more strongly with binding in the CDS exhibit increased ribosome association and translational efficiency in the KO cells. The *Zfp36* target set includes mRNAs for many types of proteins but is enriched for transcripts affecting cellular processes such as cell proliferation, apoptosis, T cell activation and others. Comparing WT and KO T cells, the authors show that the loss of *Zfp36* leads to reduced apoptosis and increased proliferation after stimulation. Using a transgenic carrying a β-Gal specific TCR, they show that these results hold true for true T cell activation by antigen, with the activated KO cells showing enhanced CD69 and CD25 induction. Thus, the loss of *Zfp36* leads to enhanced T cell activation. Generating mixed WT and KO bone marrow chimeras, they show that sorted KO cells still exhibit enhanced proliferation, but if the sorted cells are mixed back with WT this effect was reduced. It thus appears that the enhanced T cell activation is autonomous to the mutant cells but can be affected by autocrine factors if WT cells are present. Repeating some of their analyses at 3 days post stimulation rather than 4 hours, they found larger numbers and magnitudes of expression changes in the KO cells. These were not correlated with *Zfp36* binding, indicating they were indirect downstream effects, and overlapped with known signatures of T cell exhaustion. Looking specifically at proteins associated with exhaustion PD-1, ICOS, and LAG-3, they confirmed their increased expression and found them to be dependent on Th1 cytokines. Finally, they challenged the WT and KO mice with LCMV infection. They found that the KO mice mounted a more rapid response to virus, with increased CD4 and CD8 positive cells in both blood and spleen, increased IFN and TNF production, and decreased LCMV genomic RNA in the spleen early after infection.

There is a lot of data here and all the reviewers found the genomewide RNA binding and translation analyses for these proteins to be well done and useful. Although post-transcriptional control of cytokine production has been studied for many years, there is much to be learned regarding both its mechanisms and biology. The observation that *Zfp36* may be altering translation as well as mRNA decay is novel, but its underlying mechanism is not pursued. How the *Zfp36* regulatory program fits into the context of acquired immunity is also not understood, and in showing that *Zfp36* provides a brake on T cell responses, this study adds potential new understanding in this area. However, the loss of *Zfp36* alone, without the *Zfp36L1* KO, yielded often small or subtle effects. Without some assessment of the consequences of depleting both proteins, additional characterization is needed to solidify the conclusions related to the role of these proteins in T cell biology.

Essential revisions:

1\) LCMV infection should be performed in mixed chimeras to determine whether the degree to which the observed effects on the kinetics of the T cell response are cell intrinsic.

2\) One important unaddressed issue is the mechanism driving the increase in ZNF36 expression upon CD4^+^ activation. In the absence of a careful analysis of this, the authors should at least discuss what the RNA-Seq, HITS-CLIP and ribosome profiling suggests.

3\) The authors make the assumption that the heterogeneity in Figure 1A and other western blots of ZNF36 is due to differential phosphorylation. However, the blots of individual paralogs in Figure 1---figure supplement 1 suggest that these proteins run as discrete bands. It would be interesting to see the gel in Figure 1A blotted with the paralog-specific antibodies to determine if the multiple species are a result of the distinct isoforms. This is of interest as the detection of the individual species changes over time (faster migrating species dominates in the first 1-2 hours, followed by the slower migrating species).

4\) Figure 1H and many of the protein blots in Figure 2 show statistically significant differences, but are these really biologically meaningful? It seems particularly unclear that the 10% difference in IFN-γ protein in Figure 2A could give rise to the large differences in IFN-γ secretion in Figures 6 and 7. Is the latter perhaps due to an indirect effect of increased Th1 polarization? (see point 7),

5\) The proposed role of ZNF36 in repressing translation is not well supported. The results of the reporter assay in Figures 2B and C are striking, but the effect on protein is much greater than observed in the endogenous gene (Figure 2A). This may not be due to binding of ZNF36 to the UTR since mutation of the binding site has an effect even in the absence of ZNF36. (Alternatively, 293 cells may express ZNF36 -- a western blot should be done.) Or is this due to some other feature of the IFN-γ UTR? What is the result if the TNF or CD69 3\' UTR is used? Since these endogenous genes seem to show a larger response, they may give more robust results with the reporter assay.

6\) A second concern with the translation conclusion is it is unclear in Figure 3C why \"intron bound\" is used as the negative control rather than \"none\". Transcripts that are enriched for binding in the intron may well produce mRNAs whose expression or function differs between WT and KO, confounding the interpretation of the translation differences between conditions (if that is what the GSEA score reveals -- this is unclear).

7\) The authors should show what percentage of cells in the in vitro activation in Figures 1 and 6 are actually polarized to a Th1 fate. Typically only a subset of the cells actually achieve the desired fate under such in vitro conditions. Given that T cells in the ZNF36 KO mice appear predisposed to a Th1 fate, it is important to assess whether the differences observed in Figure 6 are a direct effect of ZNF36 or simply reflect that a greater percentage of cells in the activation culture are Th1 cells.

8\) It would be much better to use FoxP3 instead of CD25 to identify Tregs (e.g. in Figure 7---figure supplement 1F).

10.7554/eLife.33057.035

Author response

> Essential revisions:
>
> 1\) LCMV infection should be performed in mixed chimeras to determine whether the degree to which the observed effects on the kinetics of the T cell response are cell intrinsic.

These analyses were done for this revision, and appear in Figure 7---figure supplement 3. Quoting from the revised Results:

"To examine whether the accelerated LCMV-specific T-cell response in *Zfp36* KO mice is cell-intrinsic, infections were repeated in mixed BM chimeras. \[...\] Of note, maximum T-cell expansion was observed in mixed chimeras 7-8 days p.i., which was intermediate to the maxima observed in *Zfp36* KO (6 days) and WT (10 days) mice."

And the revised Discussion:

"In mixed BM chimeras, the response kinetics of WT and *Zfp36* KO T cells to LCMV infection were indistinguishable. \[...\] Regardless of the initiating mechanism, the observation of enhanced LCMV clearance is likely T cell-dependent, given the central role of T cells in LCMV immunity (Matloubian et al., 1994)."

> 2\) One important unaddressed issue is the mechanism driving the increase in ZNF36 expression upon CD4^+^ activation. In the absence of a careful analysis of this, the authors should at least discuss what the RNA-Seq, HITS-CLIP and ribosome profiling suggests.

We have included additional data from analyses of naïve CD4^+^ T cell RNAseq data that address this point. Quoting from the revised Results:

"The characterization of *Zfp36* as an immediate early response gene in various cell types established transcription as a mechanism of its activation-induced expression (Lai et al., 1995). \[...\] These observations indicate that post-transcriptional mechanisms regulate expression of ZFP36 paralogs in T cells."

And quoting from the revised Discussion:

"ZFP36 and ZFP36L1 expression are rapidly induced upon T cell activation, and gradually recede thereafter. \[\...\] However, the presence of its mRNA further suggests post-transcriptional control of ZFP36 paralog expression, and is consistent with functions in other contexts or stages of T cell function ((Vogel et al., 2016; Hodson et al., 2010))."

> 3\) The authors make the assumption that the heterogeneity in Figure 1A and other western blots of ZNF36 is due to differential phosphorylation. However, the blots of individual paralogs in Figure 1---figure supplement 1 suggest that these proteins run as discrete bands. It would be interesting to see the gel in Figure 1A blotted with the paralog-specific antibodies to determine if the multiple species are a result of the distinct isoforms. This is of interest as the detection of the individual species changes over time (faster migrating species dominates in the first 1-2 hours, followed by the slower migrating species).

We agree with the reviewers' interpretation -- the signal in Figure 1A reflects detection of two paralogs -- ZFP36 and ZFP36L1 -- and the balance may be shifting over time. In addition, the observed bands running well above the expected MW of ZFP36 (36 kD) are strongly consistent with previously described, hyperphosphorylated species. We have clarified and expanded our thoughts on this heterogeneity in the Results (subsection "ZFP36 dynamics during T cell activation", second paragraph).

Regarding a deeper analysis of the dynamics of individual paralogs, we can offer further insights for the reviewers' benefit. At the time of analysis, the blot in Figure 1A was stripped and re-probed with the ZFP36L1-specific antibody (this antibody also reacts with the significantly larger ZFP36L2, but none was detected).

![](elife-33057-resp-fig1){#respfig1}

Please note the diminished quality is due to the harsh conditions that were necessary for complete stripping, which was confirmed by re-probing with secondary antibody. Nonetheless, the pattern here is clearly similar to that of the pan-ZFP36 antisera, with the higher band dominating initially, and the lower band increasing over time. As in plots with pan ZFP36 sera, the higher band in these blots runs significantly above the expected MW of ZFP36/L1 (\~36 kD). Since only a single paralog is represented in the re-probed blot, we interpret the higher band as hyperphosphorylated, based on its consistency with numerous prior descriptions of ZFP36 paralog phosphorylation (Ross et al., 2015; Qiu et al., 2012; Sun et al., 2006).

As the reviewers note, a 'higher' band is the only one detected in blots with the ZFP36-specific antibody 4 hours after activation in Figure 1---figure supplement 1D. A working ZFP36-specific antibody was not identified until a year after these time courses were done, after screening many commercial products. This antibody gave a relatively low signal, even at high titers, compared to the pan-ZFP36 and ZFP36L1/2 antibodies. While sufficient to confirm loss of ZFP36 in KO cells in Figure 2---figure supplement 1D, this antibody is not suitable for a conclusive probe of paralog isoform kinetics. However, given the high homology between ZFP36 and ZFP36L1 and their similar predicted size, it is very likely the band in question (Figure 1---figure supplement 1D, ZFP36 panel) is hyperphosphorylated ZFP36, and that hypophosphorylated ZFP36 is below detection.

It is further worth noting that published RNA expression data that showed similar expression dynamics for ZFP36 and ZFP36L1 after T cell activation (for instance, the time course data from Yosef et al., 2013 -- [Author response image 2](#respfig2){ref-type="fig"}).

![](elife-33057-resp-fig2){#respfig2}

Taken together, existing evidence suggests ZFP36 and ZFP36L1 show similar patterns of expression after T cell activation. We have not included these details in the revised manuscript, because we are not aware of the necessary reagents for a full analysis and, more importantly, we lack evidence of distinct paralog functions in this context. As stated in the manuscript (Results subsection "Transcriptome-wide identification of ZFP36 target RNAs in CD4+ T cells", third paragraph), future studies may tease out differences in paralog function, but our data suggest are large degree of redundancy.

> 4\) Figure 1H and many of the protein blots in Figure 2 show statistically significant differences, but are these really biologically meaningful? It seems particularly unclear that the 10% difference in IFN-γ protein in Figure 2A could give rise to the large differences in IFN-γ secretion in Figures 6 and 7. Is the latter perhaps due to an indirect effect of increased Th1 polarization? (see point 7).

The first critical point to consider is that all of the genomic and functional analyses begin with purified, naïve T cells, and we have shown that naïve ZFP36 KO and WT CD4^+^ T cells differentiate similarly to Th1, Th17, and Treg lineages (Figure 7---figure supplement 1G, I). Therefore, the observed differences in protein levels and ribosome profiling cannot be attributed to differential Th1 skewing, and we have no evidence that loss of ZFP36 intrinsically disposes naïve T cells to a specific fate, Th1 or otherwise.

There may be understandable confusion caused by the data in Figure 7---figure supplement 1H, which shows that splenocytes stimulated directly ex vivo with PMA/ionomycin (no skewing) contain more IFNG-producing T cells in ZFP36 KO versus WT, although only marginally for CD4^+^ cells. This data was included as part of a descriptive analysis of the in vivo T-cell compartment of ZFP36 KO mice. The splenic cells producing high levels of IFNG directly ex vivo are effector and/or memory cells, and are not the population analyzed in our other experiments. This result does indicate that Th1 effector cells are more abundant in ZFP36 KO versus WT animals at the age analyzed (6 weeks). However, this accumulation probably occurs over time, and we cannot conclude it is T cell-intrinsic. Again, when naïve T cells are sorted, and analyses are conducted in a short time window, there is no detectable difference in the ability of WT and KO cells to form Th1 cells.

The second key point to consider is that genomic and functional analyses were done at an early time point (4 hours) well before full skewing has occurred. At this point, as expected and as the reviewers note, IFNG protein expression is quite low. Full differentiation to naïve cells to Th1 cells under these conditions, with high levels of IFNG expression, takes 48-72 hours. Nonetheless, analysis of this early time point was crucial because it represents peak ZFP36 expression (Figure 1) and because we have observed that likely secondary effects pre-dominate later on (Figure 6). These analyses were designed to most effectively observe the regulatory effects of ZFP36, not the maximum biological impact of any specific target, including IFNG. That said, we agree the mentioned 10% difference does not fully account for the larger ones observed in secreted levels of IFNG in Figure 6. Crucially, the latter experiment measured secreted IFNG accumulated in culture supernatants over 3 days that are also impacted by the greater expansion of ZFP36 KO cells under these conditions, due to more rapid activation (see Results subsection "Downstream effects of ZFP36 regulation"). The compounding effect of small differences over time, combined with greater cell numbers, can readily account for the larger differences at the later time point.

Overall, these points highlight two critical themes -- 1) that small effects at early time points can have a large impact in a rapidly changing and expanding cell population, such as differentiating T cells; and 2) that subtle effects on many targets, rather than large effects on individual ones, are the norm rather than the exception in post-transcriptional control. We have inserted comments in the Discussion (seventh paragraph) to make these points more effectively.

> 5\) The proposed role of ZNF36 in repressing translation is not well supported. The results of the reporter assay in Figures 2B and C are striking, but the effect on protein is much greater than observed in the endogenous gene (Figure 2A). This may not be due to binding of ZNF36 to the UTR since mutation of the binding site has an effect even in the absence of ZNF36. (Alternatively, 293 cells may express ZNF36 -- a western blot should be done.) Or is this due to some other feature of the IFN-γ UTR? What is the result if the TNF or CD69 3\' UTR is used? Since these endogenous genes seem to show a larger response, they may give more robust results with the reporter assay.

For this revision we have generated and tested new reporters based on TNF and CD69 3'UTRs, which show results very similar to the IFNG reporter (Figure 2C). The key result from these assays is that effects on protein output are significantly greater than on RNA levels, which supports the principle of translation regulation by ZFP36. Indeed the CD69 and TNF reporters show a more pronounced effect than IFNG in this regard.

As noted by the reviewers, deleting the ZFP36 binding site had an effect on GFP protein expression both in the presence and absence of transfected ZFP36. This was also observed with the TNF and CD69 reporters, indicating it is not a unique feature of the IFNG 3'UTR. Western blots in Figure 1---figure supplement 1A rule out the endogenous expression of ZFP36 in 293 cells as a confounding factor. Rather, this effect probably reflects the activity of other ARE regulatory factors in 293 cells. Nonetheless, ZFP36-dependent effects on reporter expression are clear -- we have added additional labels with fold-changes to Figure 2C and re-worked the revised results to aid interpretation.

> 6\) A second concern with the translation conclusion is it is unclear in Figure 3C why \"intron bound\" is used as the negative control rather than \"none\". Transcripts that are enriched for binding in the intron may well produce mRNAs whose expression or function differs between WT and KO, confounding the interpretation of the translation differences between conditions (if that is what the GSEA score reveals -- this is unclear).

This is the comparison that was done, and we have clarified this point with a more detailed explanation in the revised Results (subsection "ZFP36 represses target mRNA abundance and translation during T cell activation", last paragraph). The GSEA score is determined by ranking all observed transcripts by the metric of interest (in this case, translational efficiency), and examining the distribution of a designated subset (in this case, ZFP36 CLIP targets) in the whole set. The requested comparison ("target" vs. "none") is built into this design, and is the basis of the reported p-values. We included the "intron bound" set as an example of a rationally defined subset that did not show such an enrichment. This supports the specific function of CDS and 3'UTR sites in regulating translation.

> 7\) The authors should show what percentage of cells in the in vitro activation in Figures 1 and 6 are actually polarized to a Th1 fate. Typically only a subset of the cells actually achieve the desired fate under such in vitro conditions. Given that T cells in the ZNF36 KO mice appear predisposed to a Th1 fate, it is important to assess whether the differences observed in Figure 6 are a direct effect of ZNF36 or simply reflect that a greater percentage of cells in the activation culture are Th1 cells.

Addressed above with point 4). Skewing percentages are shown in Figure 7---figure supplement 1I.

> 8\) It would be much better to use FoxP3 instead of CD25 to identify Tregs (e.g. in Figure 7---figure supplement 1F).

We acknowledge the point that FoxP3 is the definitive marker for Tregs. We did not examine FoxP3 expression in splenic T cells directly ex vivo, but feel that a major difference in Treg presence in vivo would have been apparent in the enumeration of CD25-hi CD4^+^ cells, which is a widely used correlate. We did examine the capacity for iTreg induction in vitro in WT and KO FoxP3-GFP mice, and observed no significant difference (Figure 7---figure supplement 1G).

To address this concern, we have re-worded the Results and accompanying figure labels:

"Levels of CD25-hi CD4^+^ cells were not significantly different in spleens of WT and KO mice, consistent with similar levels of natural Tregs (Figure 7---figure supplement 1F). FoxP3 expression was not examined directly ex vivo, but in vitro induction of Tregs from naïve cells CD4^+^ T-cells, enumerated in FoxP3-GFP mice, was not different between WT and KO (Figure 7---figure supplement 1F)."

[^1]: Regeneron Pharmaceuticals, Tarrytown, United States.
